Page last updated: 2024-08-16

ticlopidine and thiophenes

ticlopidine has been researched along with thiophenes in 764 studies

Research

Studies (764)

TimeframeStudies, this research(%)All Research%
pre-1990193 (25.26)18.7374
1990's0 (0.00)18.2507
2000's140 (18.32)29.6817
2010's428 (56.02)24.3611
2020's3 (0.39)2.80

Authors

AuthorsStudies
Abiko, Y; Ashida, S1
Altomonte, F; Armani, U; Griffanti-Bartoli, F; Piana, A; Pitton, L1
Dechavanne, M; Ghazi, I; Lagarde, M1
Horikoshi, S; Mitsuka, S; Miyagi, O; Nukui, H; Ohe, C; Sasaki, H; Shibasaki, T; Tamada, J; Toyoda, O1
Bonnetblanc, JM; Julia, A; Rigaud, M1
Kienast, J; Verstraete, M1
Cannizzaro, S; Davì, G; Giubilato, A; Strano, A1
Bronchi, GF; Carini, A; Karavassili, M; Tesi, M1
Campisi, D; Davì, G; Francavilla, G; Paterna, S; Pinto, A; Strano, A1
Chapillon, M; Enon, B; Jacob, JP; Lavenet, F; Riberi, P; Spiesser, R1
Hurault De Ligny, B; Kessler, M; Louis, J; Renoult, E; Vagner, JC1
Asaka, M; Iida, H; Izumino, K; Mizumura, Y; Sasayama, S1
Abou-Khalil, S; Abou-Khalil, WH; Yunis, AA2
Inoue, H; Kawada, S; Koide, S; Ogawa, J; Shohtsu, A; Tsurumi, T1
Boissel, JP; Destors, JM; Gauthier, E; Lelong, S1
Hayashida, N1
Ojeda, G; Portolés, A; Portolés, MP; Rojo, JM1
Capecchi, PL; Ceccatelli, L; Di Perri, T; Laghi Pasini, F; Orrico, A; Pasqui, AL1
Hongo, T; Kwan, T; Setaka, M1
Grimaldi, MG1
Harker, LA2
Cerbone, AM; Di Minno, G; Iovine, C; Mancini, M; Mattioli, PL; Turco, S1
Benoit, G; Brasseur, L; Charpentier, B; Fries, D; Lang, P; Plaisant, B1
Berglund, U; Wallentin, L3
Alberca, I; Cattaneo, M; Coccato, MP; Faioni, E; Mannucci, PM; Mari, D; Vianello, L; Vicente, V1
Brown, BG; Chesebro, JH; Ekeström, S; Harker, LA; Henderson, AH; Jewitt, DE; Oliver, MF; Sleight, P; Verstraete, M1
Bowles, MJ; Khurmi, NS; Kohli, RS; Raftery, EB1
Katori, M; Kawana, S; Nishiyama, S; Ohta, M1
Hatsuoka, M; Kashii, A; Sasaki, K; Seiki, M1
Akiyama, K; Endo, K; Kobayashi, S; Kohata, K; Mori, M; Morita, A1
Lecompte, T; Lecrubier, C; Potevin, F; Samama, M1
Grosso, B; Nyffeneger, G; Pistone, AM; Podestà, F; Raviolo, E; Testa, D; Toselli, P1
Arpaia, MR; del Guercio, R; Leonardo, G1
Cepelák, V; Köcher, P; Opatrný, K; Racek, J1
Edgerton, TA; Faust, KB; Geisinger, KR; Hansen, KJ; Howe, HR; Kon, ND; Meredith, JH1
Almirall, L; Bastida, E; Escolar, G; Ordinas, A1
Imai, Y; Matsumura, H; Nishikawa, K; Terashita, Z1
Di Perri, T1
Drouet, L1
Anderton, JL; Burnet, ME; Fiskerstrand, CE; Thompson, IW; Williams, P1
Goebel, N; Krayenbühl, HP; Pfluger, N; Rothlin, ME; Senning, A; Speiser, K; Steinbrunn, W; Turina, M1
Gröntoft, KC; Gutierrez, A; Mulec, H; Olander, R1
Gormsen, J; Kjøller, E; Knudsen, JB; Skagen, K1
Berglund, U; von Schenck, H; Wallentin, L1
Aversa, F; Del Favero, A; Giordano, G; Guerciolini, R1
Díez, M; Fernández, A; Gil, M; Lasierra, J; Velázquez, E; Viladés, E1
Castaigne, JP; Labie, D; Sablayrolles, M; Wajcman, H2
Hashimoto, N; Kholoussy, AM; Kumashiro, R; Matsumoto, T; Piotrowski, JJ1
Bernat, A; Maffrand, JP; Roncucci, R; Vallée, E1
Cattaneo, M; Groves, HM; Kinlough-Rathbone, RL; Mustard, JF; Packham, MA; Somers, DA; Winocour, PD1
de Artaza, M; de Teresa, E; Lorenz, P; Marin, MC; Martín-Júdez, V; Ugarte, M1
Takayama, T2
Loveday, BE; Nuttall, A; Smith, HJ1
Cohn, M; Eldor, A; Matzner, Y1
Lotti, G; Marmont, AM; Martinengo, M; Morgano, A; Nati, S1
Charbonnier, R; Pistone, MA; Resegotti, L; Testa, D; Toselli, P; Vivalda, S1
Avello, F; Carmona, J; Criado, A; Juffé, A; Otero, C1
Glukhov, AI; Goriunov, VS; Kirichenko, AA; Smirnova, LA1
Almeida-Dias, A; Pina-Cabral, JM; Ribeiro-da-Silva, A1
Alessandri, C; Balsano, F; Ghiselli, A; Iuliano, L; Perrone, A; Violi, F1
Battocchio, F; Crociani, ME; Fabris, F; Girolami, A; Randi, ML1
Glusa, E1
Verstraete, M2
Caen, JP; Dunn, FW; Lee, H; Soria, C; Soria, J; Thomaidis, A1
Fox, KM; Jonathan, A; Selwyn, AP1
Breddin, HK; Pauliks, V; Weichert, W1
Offerhaus, L1
Cacciatore, L; De Marco, F; Giardina, MG; Matarazzo, M1
Tullio, D1
Gragnoli, G; Signorini, AM; Tanganelli, I1
Garrido García, H; Martín Infante, A; Rivas Marín, J; Vilaplana Serrano, F1
Najean, Y; Poirier, O1
Claas, FH; de Fraiture, WH; Meyboom, RH2
Alessandri, C; Balsano, F; Frattaroli, S; Ghiselli, A; Violi, F1
Abbate, R; Breschi, C; Costanzo, G; Favilla, S; Gensini, GF; Neri Serneri, GG1
Ritchie, JL; Stratton, JR1
Numano, F1
Kester, RC1
Carniti, E; Fiorini, L; Iezzi, BG; Sbalzarini, G1
Díaz, R; Portolés, A; Rojo, JM1
Avellone, G; Davì, G; Mandalà, V; Novo, S; Pinto, A; Raneli, G; Riolo, FP1
Daveloose, D; Leterrier, F; Molle, D; Sablayrolles, M1
Gaillard, JL; Kher, A; Lecompte, T; Samama, M1
Eugene, C; Gury, B; Lefebvre, JF; Quevauvilliers, J1
Arimura, GK; Lo, L; Yunis, AA1
Kawai, C1
Andriani, A; Beni, A; Chiappetta, MG; Fabiani, M; Mosiello, G1
Cove, DH; Neumann, V; Shapiro, LM; Trethowan, N1
Picard-Fraire, C2
Bruno, JJ1
Almasio, P; Ascari, E; Piovella, F; Ricetti, MM; Samaden, A; Semino, G1
Hess, H; Ingrisch, H; Mietaschk, A; Stiegler, H; Trampisch, HJ1
Gordon, JL1
Blanchard, J; Panak, E; Roe, RL1
Katsumura, T1
David, JL; Limet, R; Rigo, P1
Cabannes, R; Castaigne, JP; Lonsdorfer, J; Ondo, A; Plassard, A; Zohoun, I1
Baarsma, GS; Henkes, HE; Houtsmuller, AJ; Klompe, M; Tijssen, J; Vermeulen, JA; Zahn, KJ1
Mirouze, J1
Kikuchi, H; Kitamura, K; Mizukami, M; Ono, H1
Hass, WK; Kamm, B1
Tohgi, H1
Ellis, D; Gent, M1
Day, HJ1
Al-Hasani, SF; Kioy, P; Savidge, GF; Semple, MJ1
Bonta, IL; de Wit, CM; Vincent, JE; Zijlstra, FJ1
Almasio, P; Giddings, JC; Piovella, F; Ricetti, MM; Thomas, JE1
Goebel, N; Pfluger, N; Rothlin, M; Speiser, K; Turina, M1
Gutiérrez González, JR; Méndez Martín, A; Ortiz González, A1
Bruno, JJ; Chang, LF; McSpadden, MM; Yang, D1
Díez, MM; Fernández, A; Gil, M; Lasierra, J; Velázquez, E; Viladés, E1
Butler, KD; White, AM1
Naruse, T; Ogawa, S1
Carfagna, S; Carrieri, P; Fioretti, A; Indaco, A; Orefice, G1
Abou-Khalil, S; Abou-Khalil, WH; Lim, LO; Yunis, AA1
Herce Muñoz, M1
Cánovas, M; Navarro, C; Padró, T; Villaverde, C1
Caulet, T; de Lacharrière, O; Kalis, B; Léonard, F; Renard, T; Triller, R1
Barbe, G; Gruyer, P; Guyot, L; Lapeyrère, X; Saint-Paul, B1
Pinon, JF1
Ebata, H; Harada, M; Hidaka, T; Ishii, Y; Mashiko, N; Nouno, R; Satoh, K; Tanikawa, K; Ueda, H1
Hanson, SR; Harker, LA1
d'Avenia, V; di Minno, G; Iovine, C; Mattioli, PL; Turco, S1
Goyan, JE1
Berthe, J; Combes, M; Garbay, TM; Gouy, D; Lacheretz, F; Mazué, G; Remandet, B; Vic, P1
Bogui, P; Cabannes, R; Castaigne, JP; Dosso, Y; Lenormand, E; Lonsdorfer, J; Otayeck, A1
Bernat, A; Delebassée, D; Maffrand, JP; Tissinier, A; Vallée, E1
Girard, P; Lecrubier, C; Noire, P; Samama, M1
Battais, E; Bonne, C1
López-Trigo Picho, J; Sancho Rieger, J1
Chevigné, M; David, JL; Limet, R; Rigo, P1
Kholoussy, AM; Kumashiro, R; Matsumoto, T; Pavlides, CA1
de Zeeuw, RA; Drenth, BF; Ghijsen, RT; Overzet, F; Rurak, A; van der Voet, H1
Chowhan, ZT; Yang, IC1
Blanchard, J; Maffrand, JP; Panak, E; Picard-Fraire, C; Roncucci, R; Vallée, E1
Bono, F; Cambi, V; Castiglioni, A; De Gasperi, T; Menta, R; Savazzi, GM; Zanelli, P1
Paris, J1
Blanchard, J; Blatrix, C; Panak, E; Thébault, JJ2
Bertelé, V; de Gaetano, G2
Aurell, M; Blohmé, G; Jagenburg, R; Larsson, O; Nyberg, G; Westberg, NG1
Aukland, A; Hawker, RJ1
Bando, H; Tsubura, E; Yamashita, T1
Lasierra, J; Martínez Peñuela, JM; Sánchez Casajús, A; Velázquez, E1
Benveniste, J; Chignard, M; Delabassee, D; Delautier, D; Lalau Keraly, C1
Andriani, A; Chiappetta, MG; Fabiani, M1
Caen, JP; Lee, H; Paton, RC; Ruan, C1
Bonta, IL; vd Veerdonk, MA; Vincent, JE; Zijlstra, FJ1
Chevolet, C; Dresse, A; Grosdent, JC; Reiters, GM1
Conard, J; Horellou, MH; Lecrubier, C; Samama, M1
Ariganello, M; Borzi, M; Cannata, D; Filice, A; Galante, A; Lenci, R; Sommariva, L1
Dohi, S; Mayumi, T1
Furukawa, Y; Kondo, M; Murakami, M; Takemura, S; Yoshikawa, T1
Benghozi, R; Bienvenu, MP; Castaigne, A1
Kamiya, K; Katsumura, T; Mishima, Y; Sakaguchi, S; Sakuma, A; Tanabe, T1
Aukland, A; George, AJ; Hurlow, RA; Stuart, J1
Lefort, J; Randon, J; Vargaftig, BB1
Bauters, F; Canuel, C; de Gramont, A; Degos, L; Krulik, M; Marty, M; Najean, Y1
Glasson, S; Tillement, JP; Zini, R1
Donner, M; Nicolas, A; Solagna, S; Stoltz, JF; Verry, M1
Egbring, R; Klingemann, HG1
Blanchard, J; Blatrix, C; Panak, E; Thébault, J1
Davies, JA; Doig, RL; Kester, RC; McNicol, GP; Menys, VC; Paton, RC; Tindall, H1
Alberani, M; Manotti, C; Megna, A; Poli, T; Potì, R1
Bush, H; Flamenbaum, W; Gross, ML; Hamburger, RJ; Weinger, R1
Dewanjee, MK; Fuster, V; Kaye, MP; Murphy, KP; Pumphrey, CW; Vlietstra, RE1
Aubert, D; Ferrand, C; Loubrie, JC; Tuong, A; Tuong, CC1
Bousser, MG; Conard, J; Horellou, MH; Lecrubier, C; Samama, M; Scarabin, PY1
Kawaguchi, Y; Kobayashi, K; Koshikawa, S; Maeda, K; Naito, C; Shimizu, N1
Brommer, EJ1
Fujie, K; Fujie, Y1
Chap, H; Douste-Blazy, L; Simon, MF1
Bouyssou, A; Cuong, TG; Paret, J; Tuong, A1
Chow, YP; Chowhan, ZT1
Ishihara, M; Kinjo, M; Kohga, S; Ogawa, H; Tanaka, K; Tanaka, N1
Kawaguchi, S; Kobayashi, K; Maeda, K; Narita, M; Ohbayashi, S; Ohta, K; Saito, A; Shinzato, T; Usuda, M1
Abiko, Y; Ashida, S; Sakuma, K1
Akashi, A; Hirohashi, M; Kasahara, A; Tamura, K; Watanabe, K1
Bousser, J; Bousser, MG; Conard, J; Lecrubier, C1
Lindsay, R; Nunn, B1
Jogestrand, T; Johnsson, H; Kirstein, P; Olsson, AG1
Curtet, JM; Guilmet, D; Renner, C1
Asai, F; Inoue, T; Koike, H; Ogawa, T; Sugidachi, A1
Dalvie, DK; O'Connell, TN1
Asai, F; Jakubowski, JA; Niitsu, Y; Sugidachi, A1
Antman, EM; Behounek, BD; Braunwald, E; Carney, RJ; Lazzam, C; McCabe, CH; McKay, RG; Murphy, SA; Weerakkody, G; Winters, KJ; Wiviott, SD1
Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ1
Lowry, DR; Malinin, AI; Meilman, H; Midei, MG; Serebruany, VL1
Serebruany, VL8
Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD1
Gurbel, PA; Tantry, US1
Asai, F; Brandt, JT; Freestone, S; Hirota, T; Jakubowski, JA; Matsushima, N; Naganuma, H; Winters, KJ1
Bliden, KP; Gurbel, PA; Tantry, US1
Brandt, JT; Farid, NA; Jakubowski, JA; Naganuma, H; Payne, CD; Small, DS; Weerakkody, G; Winters, KJ; Wiviott, SD1
Cattaneo, M5
Araki, H; Batory, LA; McInnis, CE; Njardarson, JT; Rogers, E1
Huber, K; Schrör, K; Siller-Matula, J; Wojta, J1
Brandt, JT; Darstein, C; Ernest, CS; Farid, NA; Jakubowski, JA; Payne, CD; Salazar, DE; Small, DS; Winters, KJ1
Brandt, JT; Farid, NA; Jakubowski, JA; Lachno, DR; Li, YG; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ1
Asai, F; Hagihara, K; Hashimoto, M; Jakubowski, JA; Kurihara, A; Niitsu, Y; Ogawa, T; Sugidachi, A1
Brandt, JT; Farid, NA; Jakubowski, JA; Naganuma, H; Payne, CD; Warner, MR; Weerakkody, GJ; Winters, KJ; Zhu, J1
Brandt, JT; Jakubowski, JA; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ1
de Lemos, JA; Wiviott, SD1
Brandt, JT; Close, SL; Ernest, CS; Farid, NA; Iturria, SJ; Lachno, DR; Payne, CD; Salazar, D; Winters, KJ1
Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD1
Bhatt, DL1
Asai, F; Hashimoto, M; Isobe, T; Jakubowski, JA; Niitsu, Y; Ogawa, T; Otsuguro, K; Sugidachi, A1
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ1
Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ1
Angiolillo, DJ; Antman, EM; Braunwald, E; Cairns, R; Frelinger, AL; Hod, H; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Montalescot, G; Murphy, SA; Neumann, FJ; O'Donoghue, M; Trenk, D; Wiviott, SD1
Huber, K; Schrör, K1
Angiolillo, DJ1
Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ3
Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF; Sugidachi, A1
Brandt, JT; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Weerakkody, GJ; Winters, KJ1
Schaerlig, E1
Serebruany, V2
Di Sciascio, G; Pasceri, V; Patti, G1
Paulus, W; Riggert, J; von Lewinski, F1
Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD1
Eikelboom, JW; Hankey, GJ; Langton, PE1
De Servi, S; Lettino, M1
Ajani, AE; Lefkovits, J1
Antman, EM; Braunwald, E; Murphy, SA; Wiviott, SD1
Dovlatova, NL; Heptinstall, S; Jakubowski, JA; Sugidachi, A1
Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD1
Alvarez, W1
Haber, SL; Riley, AB; Tafreshi, MJ1
Dovlatova, N; Heptinstall, S; Johnson, A1
Alberts, MJ; Hanley, DF; Serebruany, VL1
Barker, CM; Price, MJ1
Sosnowski, C1
Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD1
Ramaraj, R1
Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF1
Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD1
Ernest, CS; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ1
Preobrazhenskiĭ, DV1
Klauss, V; Krötz, F; Sohn, HY1
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ1
Wiviott, SD1
Eikelboom, JW; Hirsh, J; Raju, NC1
Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE1
Goodsaid, FM1
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ1
Farid, NA; Hagihara, K; Ikeda, T; Ito, T; Kurihara, A; Miura, S; Nishiya, Y; Tajima, M1
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ1
Cairns, JA; Eikelboom, J1
Dachs, R; Darby-Stewart, A; Graber, MA1
De Servi, S; Mariani, G; Mariani, M1
Farid, NA; Hagihara, K; Ikeda, T; Kazui, M; Kurihara, A; Nishiya, Y1
Calatzis, A1
Kopyleva, O; Serebruany, V; Shalito, I1
Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC1
Akram, F; Akram, S; Postuła, M1
Faxon, DP; Freedman, JE1
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Olofsson, S; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ1
Stone, GW3
Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD1
Giugliano, RP; Thomas, D1
Farid, NA; Fusegawa, K; Hagihara, K; Ikeda, T; Ikenaga, H; Kazui, M; Kurihara, A; Nanba, T; Okazaki, O; Takahashi, M1
Sabatine, MS1
Antonino, MJ; Gurbel, PA; Mahla, E; Tantry, US1
Angiolillo, DJ; Capranzano, P; Ferreiro, JL1
Butt, M; Lip, GY; Shantsila, E; Siddique, A1
Gleason, PP; Kjesbo, NK; Schafer, JA1
Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ1
Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP1
Marzot, F; Pengo, V1
Cryer, B1
Das, K; Das, P; Koshy, SK; Robinson, A1
Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD1
Price, MJ3
Motovska, Z; Widimsky, P1
Floyd, J; Wolfe, S1
Gladding, P; Webster, MW1
Shil, AB; Strohm, MP1
Barthélémy, O; Beygui, F; Collet, JP; Funck-Brentano, C; Hulot, JS; Montalescot, G; Pena, A; Silvain, J1
Makarov, LM; Serebruany, VL1
Rees, C; Spinler, SA1
Curtiss, FR; Fairman, KA1
Eberli, FR; Roffi, M1
Petersen, KU1
Alban, S; Dingermann, T1
Alban, S1
Breitkreutz, J1
Kereiakes, DJ1
Wallentin, L1
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Ni, L; Payne, CD; Rohatagi, S; Small, DS; Winters, KJ1
Duggan, ST; Keating, GM1
Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD1
Kumar, A; Roberts, DH1
Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H1
Hayden, EC1
Dauerman, HL1
Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C1
Farid, NA; Hagihara, K; Honda, K; Ikeda, T; Kazui, M; Kurihara, A; Okazaki, O; Yoshiike, M1
Schömig, A1
Kastrati, A; Sibbing, D1
Antman, EM; Bates, ER; Braunwald, E; Close, SL; Hautvast, RW; Mega, JL; Michelson, AD; Murphy, SA; O'Donoghue, ML; Rozenman, Y; Sabatine, MS; Shen, L; Ver Lee, PN; Wiviott, SD1
Schrör, K1
Farid, NA; Hagihara, K; Ikeda, T; Kurihara, A; Nishiya, Y; Okazaki, O; Okudaira, N1
Collet, JP; Hulot, JS; Montalescot, G1
Menon, V; Raymond, C1
Oberpichler-Schwenk, H1
Abu-Fadel, M; Norgard, NB1
Eshaghian, S; Kaul, S; Shah, PK1
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J1
Dobesh, PP1
Baker, WL; Reinhart, KM; White, CM1
Farid, NA; Kurihara, A; Wrighton, SA1
Lazar, LD; Lincoff, AM1
del Río, A; Heras, M1
Guerra, DR; Tcheng, JE1
Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S1
Jilma, B; Krumphuber, J; Siller-Matula, JM1
Bal dit Sollier, C; Barthélémy, O; Beygui, F; Cohen, R; Collet, JP; Drouet, L; Henry, P; Lim, P; Luo, J; Marshall, D; Meuleman, C; Montalescot, G; Petitjean, H; Sideris, G1
Solomon, S; Vacek, JL1
Cattaneo, M; Podda, GM1
Lip, GY; Shantsila, E; Tapp, L1
Farid, NA; Jakubowski, JA; Kelly, R; Kothare, P; Li, YG; Natanegara, F; Ni, L; Payne, CD; Richard Lachno, D; Salazar, DE; Small, DS; Teng Loh, M; Tomlin, M; Winters, KJ; Yuen, E1
Banning, AP; Bedogni, F; Bhindi, R; Biondi Zoccai, GG; Brambilla, N; Lanotte, S; Latini, RA; Laudisa, ML; Pizzocri, S; Testa, L; Valgimigli, M; Van Gaal, WJ1
Islam, AM; Patel, PM1
Fareed, J; Jeske, WP; Mousa, SA1
Gladding, P; Webster, M; White, H1
Guo, KW; Tan, JW1
Aylward, PE; Behan, MW; Chew, DP1
Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ1
Bareiss, P; Kessler, L; Morel, O; Ohlmann, P1
Abbate, R; Crea, F; De Servi, S; Filippi, E; Gensini, GF; Golinos, P; Savonitto, S1
Chew, DP; Prakash, R; Wong, YW1
Neumann, FJ1
Amin, AP; Marso, SP1
Duconge, J; Ruaño, G; Seip, RL1
Dixon, SR; Grines, CL; O'Neill, WW1
Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A1
Horowitz, JD; McKinnon, RA; Sorich, MJ; Vitry, A; Ward, MB1
Erdem, G; Flather, MD; Geisler, T1
Bagust, A; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Fleeman, N; Greenhalgh, J; Kolamunnage-Dona, R; McLeod, C; Proudlove, C; Saborido, CM1
Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS1
Armstrong, PW; Brown, E; Chin, CT; Fox, KA; Lokhnygina, Y; Marshall, DA; Ohman, EM; Petitjean, H; Prabhakaran, D; Roe, MT; White, HD1
Boonbaichaiyapruck, S; Ge, J; Goh, YS; Hong, BK; Hou, CJ; Pinton, P; Zhu, J1
Gratsianskiĭ, NA1
Pakhomov, IaM2
Antman, EM; Braunwald, E; Wiviott, SD1
Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM1
Aïssaoui, N; Danchin, N1
Gurbel, PA; Mahla, E; Metzler, H; Tantry, US1
Antman, EM; Braunwald, E; Close, SL; Mega, JL; Sabatine, MS; Shen, L; Simon, T; Walker, JR; Wiviott, SD1
Abbate, R; Giusti, B1
Hallström, S; Jakubowski, A; Koidl, B; Lang, P; Mächler, H; Pelzmann, B; Zorn-Pauly, K1
Laizure, SC; Parker, RB1
Angiolillo, DJ; Costigan, TM; Deraad, R; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF1
Braber, TL; Van Der Have-Roeffel, SM; van Werkum, JW; Verheggen, PW1
Fletcher, B; Thalinger, KK1
Ancrenaz, V; Besson, M; Daali, Y; Dayer, P; Desmeules, J; Fontana, P; Samer, C1
Ferrandis, R; Gómez-Luque, A; Llau, JV; Sierra, P1
Abraham, NS; Antman, EM; Bhatt, DL; Bjorkman, DJ; Clark, CB; Furberg, CD; Hlatky, MA; Johnson, DA; Kahi, CJ; Laine, L; Mahaffey, KW; Quigley, EM; Scheiman, J; Sperling, LS; Tomaselli, GF2
Bhavaraju, K; Gartner, TK; Georgakis, A; Jin, J; Kunapuli, SP; Nurden, A; Nurden, P; Tomiyama, Y1
Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C1
De Rosa, G; Napodano, M; Padrini, R; Pengo, V; Plebani, M; Silvano, M; Zambon, CF1
Antman, EM; Baracioli, L; Braunwald, E; Giugliano, RP; Heuer, H; Lotan, C; Merkely, B; Murphy, SA; Ruff, CT; Schersten, F; Seabro-Gomes, R; Wiviott, SD1
Silber, S1
Cannon, C; Croce, K; Kirshenbaum, J; Manica, A; Marchini, J; Morrow, D; Resnic, F1
Armani, AM1
Angiolillo, DJ; Tello-Montoliu, A; Tomasello, SD1
Minarelli, M; Valgimigli, M1
Frey, N; Ivandic, B1
Ağırbaşlı, M; Cinçin, A; Güvenç, H1
Endres, HG; Engelhardt, A; Kaiser, AF; Krüger, JC; Kusber, A; Lask, S; Mügge, A; Neubauer, H; Pepinghege, F1
Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B1
Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD1
Baker, BA; Effron, MB; Jakubowski, JA; Kulkarni, MP; Li, YG; Luo, J; Miller, DL; Small, DS; Winters, KJ; Zhu, B1
Engelen, S; Sinnaeve, P; Van Damme, H; Verhamme, P1
Hamm, CW; Rassaf, T1
Achar, S1
Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M1
Smetana, GW; Srour, JF1
Lange, CG1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Silber, S; Steiger, H; Weil, J; Zugck, C1
Scharf, RE1
Baty, SR; Griffith, CB; Phillippe, HM1
Storey, RF1
Briongos Figuero, S; de Juan-Bagudá, J; Martí-Sánchez, D; Salido-Tahoces, L1
Alexopoulos, D; Athanassiadou, A; Davlouros, P; Dimitropoulos, G; Hahalis, G; Kassimis, G; Stavrou, EF; Xanthopoulou, I1
Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J1
Behr, T; Behr, W; Kuch, B; von Scheidt, W1
Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M1
Cattaneo, GJ; Cattaneo, M; Podda, GM1
Easton, JD1
Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD1
Moliterno, DJ; Rajan, L1
Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC1
Martin, MT; Nutescu, EA; Spinler, SA1
Kanadiya, MK; Koshal, VB; Singhal, S1
Ferro, A; Passacquale, G1
Close, SL; Farid, NA; Ho, M; Jakubowski, JA; Kelly, RP; Natanegara, F; Shen, L; Small, DS; Walker, JR; Winters, KJ1
Antman, EM; Braunwald, E; Costigan, TM; Frelinger, AL; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Neumann, FJ; Trenk, D; Wiviott, SD1
Carballo, D; Carballo, S; Keller, PF; Roffi, M1
Flaherty, MP; Johnston, PV; Rade, JJ1
Byrne, RA; Hausleiter, J; Laugwitz, KL; Orban, M; Sibbing, D1
Alexopoulos, D1
Alber, HF; Frick, M; Huber, K; Pachinger, O1
Bonello, L; de Labriolle, A; Doazan, JP; Lemesle, G1
Anderson, RA; Bundhoo, SS; Dada, J; Halcox, JP; Harris, R; James, PE; Lang, D; Sagan, E1
Abell, LM; Liu, EC1
Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D1
Bernlochner, I; Contant, CF; Guo, J; Hochholzer, W; Kastrati, A; Mega, JL; Morath, T; Neumann, FJ; O'Donoghue, ML; Sabatine, MS; Schömig, A; Sibbing, D; Stratz, C; Trenk, D; Valina, CM; Wiviott, SD1
Beddingfield, R; Held-Godgluck, BM; Peppard, SR1
D'Urbano, M; De Servi, S; Navarese, EP; Savonitto, S1
Rayoo, R; Sharma, N; van Gaal, WJ1
Alexopoulos, D; Davlouros, P; Hahalis, G; Mavronasiou, E; Panagiotou, A; Plakomyti, TE; Xanthopoulou, I1
Alexopoulos, D; Davlouros, P; Fourtounas, C; Goumenos, D; Kassimis, G; Komninakis, D; Panagiotou, A; Xanthopoulou, I1
Danenberg, HD; Raccah, BH; Shalit, M1
Angiolillo, DJ; Calvi, V; Capodanno, D; Capranzano, P; D'Urso, L; Miccichè, E; Tamburino, C1
Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J2
Bae, JP; Cohen, DJ; Graham, JB; Magnuson, EA; Mauskopf, JA; Meadows, ES; Ramaswamy, K; Zagar, AJ1
Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Finzi, J; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J1
Alexopoulos, D; Plakomyti, TE; Xanthopoulou, I1
Basra, SS; Lakkis, NM; Tsai, P1
Barakoti, M; Neupane, P; Pant, S; Ramesh, KC1
Chopra, P; Klaustermeyer, WB; Verma, P1
Ikeda, Y; Isshiki, T; Kimura, T; Ogawa, H; Yokoi, H1
Collet, JP; De Luca, L; Wouter Jukema, J1
Damman, P; de Winter, RJ; James, SK; Kuijt, WJ; Woudstra, P1
Becker, RC; Cutlip, DE; Dauerman, HL; French, PA; Granada, JF; Price, MJ; Smyth, SS; Steinhubl, SR1
Braunwald, E1
Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL1
Janknegt, R; Ruiters, L; Ten Cate, H1
Davies, JE; Francis, DP; Nijjer, SS1
Castriota, F; Grzesk, E; Grzesk, G; Kozinski, M; Krzyzanowski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM1
Gurbel, PA; Jeong, YH; Ohman, EM; Tantry, US1
Kern, MJ1
Hsu, PI1
Mutnick, JL1
Mackay, SM; Tcheng, JE1
Contractor, H; Ruparelia, N1
Baker, BA; Bernlochner, I; Brown, PB; Gupta, N; Jakubowski, JA; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Winters, KJ; Zhou, C1
Carbonell-Porras, A; Fernández-Ruiz, M; García-Reyne, A; López-Medrano, F1
Coulter, CJ; Montandon, SV1
Grześk, G; Koziński, M; Kubica, J1
Grajek, S1
Gong, Y; Jiao, B; Lv, F; Qi, X; Shan, J; Sun, H; Yuan, F; Zhang, B; Zheng, W; Zhu, Y1
Askari, AT; Stephens, JC1
Bristot, L; Campo, G; Ferrari, R; Gambetti, S; Monti, M; Parrinello, G; Tebaldi, M; Valgimigli, M1
Bradley, SM; Guzauskas, GF; Hughes, DA; Veenstra, DL1
Cavallari, LH; Schumock, GT1
Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES1
Dick, A; Druce, I; Froeschl, M; Glover, C; Gollob, MH; Goncalves, S; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, E; Roberts, JD; So, DY; Stewart, A; Wells, GA1
Harding, SA; Johnston, LR; La Flamme, AC; Larsen, PD; Michel, JM; Simmonds, MB1
Goss, FR; Pauker, SG1
Angiolillo, DJ; Gawaz, M; Jakubowski, JA; Kastrati, A; Müller, U; Neumann, FJ; Richardt, G; Stone, GW; Trenk, D1
Ferro, A; Floyd, CN; Passacquale, G1
Angiolillo, DJ; Azmoon, S1
Lyseng-Williamson, KA1
Mustonen, P; Puurunen, M1
Halperin, JL; Varughese, CJ1
Bessereau, J; Bonello, L; Camoin-Jau, L; Paganelli, F; Uhry, S1
Chen, CH; Lin, CJ; Uang, YS; Yang, JC1
Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA1
Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ2
Christ, G; Dechant, C; Delle-Karth, G; Francesconi, M; Gouya, G; Jilma, B; Maurer, G; Podczeck-Schweighofer, A; Ruzicka, K; Siller-Matula, JM1
Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T1
Bounthavong, M; Madkour, N1
Gupta, A; Hirst, J; McKay, RG; Rai, M; Ruaño, G; Seip, RL; Thompson, PD1
Freynhofer, MK; Höchtl, T; Huber, K; Mahla, E; Prüller, F1
Heptinstall, S; Joshi, R; Wijeyeratne, YD1
Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ1
Ahmad, S; Storey, RF1
Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A1
Bhatt, DL; Kar, S1
Barn, K; Steinhubl, SR1
Grove, EL; Hvas, AM; Kristensen, SD1
Carrié, D; Garcia, C; Lhermusier, T; Mejean, S; Sié, P; Voisin, S1
Budaj, A; Gurbel, PA; Tantry, US1
Gurbel, PA; Jeong, YH; Tantry, US1
Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I1
Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY1
Limper, U; Lynch, J1
Chan, KH; Chan, MY; Lee, CH; Li, Y; Low, A; Phua, QH; Richards, MA; Roe, MT; Sia, W; Sim, TB; Tai, BC; Tan, HC; Teo, SG; Yeo, TC1
Huber, K1
Harrison, P1
Bernlochner, I; Braun, S; Kastrati, A; Koch, W; Mayer, K; Morath, T; Schömig, A; Schulz, S; Sibbing, D1
Bernlochner, I; Sibbing, D1
Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ1
Alexopoulos, D; Athanassiadou, A; Damelou, A; Davlouros, P; Hahalis, G; Kassimis, G; Stavrou, EF; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I1
Chan, MY; Li, Y1
Brown, PM; Gladding, P; Panattoni, L; Te Ao, B; Webster, M1
Kastrati, A1
Badr Eslam, R; Calatzis, A; Gremmel, T; Koppensteiner, R; Lang, IM; Panzer, S1
Benedetti, G; Biondi-Zoccai, G; Calcagno, S; Canali, E; Di Roma, A; Fedele, F; Guadagni, F; Lucisano, L; Mancone, M; Palmirotta, R; Pennacchi, M; Sardella, G; Stio, RE1
Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E1
Angiolillo, DJ; Bergmeijer, T; Brown, PB; Erlinge, D; Foley, D; Jakubowski, JA; James, S; Luo, J; Moser, B; Small, DS; Ten Berg, J; Wagner, H; Winters, KJ; Zhou, C1
Alessi, MC; Beguin, S; Bonnet, JL; Cuisset, T; Dubois, N; Dutour, A; Gaborit, B; Loosveld, M; Loundou, AD; Morange, PE; Moro, PJ; Quilici, J1
Arthur, AS; Hoit, DA; Jones, GM; Twilla, JD2
Choi, KN; Chung, SR; Do, U; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Kim, HJ; Seo, JS; Yang, TH1
Armstrong, JM; Bandarenko, N; Barnato, SE; Bennett, CL; Carey, PM; Chen, F; Chen, H; Clark, WF; Cursio, JF; Danielson, C; Dunn, BL; Fujimura, Y; Jacob, S; Kiss, JE; Kwaan, HC; Matsumoto, M; McKoy, JM; Ortel, TL; Pandey, DK; Qureshi, ZP; Raife, TJ; Raisch, DW; Rock, G; Sarode, R; Weiss, I; Winters, JL; Zheng, XL1
Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C1
Abtan, J; Aubry, P; Barthélémy, O; Belle, L; Beygui, F; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Henry, P; Kerneis, M; Monségu, J; Montalescot, G; Motreff, P; O'Connor, SA; Pouillot, C; Rangé, G; Rousseau, H; Sabouret, P; Saint-Etienne, C; Silvain, J; Van Belle, E; Vicaut, E1
Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G1
Baeriswyl, G; Cook, S; Goy, JJ; Lehmann, S; Lehner, C; Oberhänsli, M; Puricel, S; Stauffer, JC; Togni, M1
Bolognese, L; De Servi, S1
Chen, X; Fan, Z; Li, N; Liu, Q; Lu, Y; Qiu, Z; Song, L; Tian, F; Wang, X1
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A1
Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K1
Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A1
Amann, M; Hochholzer, W; Leggewie, S; Neumann, FJ; Nührenberg, TG; Ristau, I; Stratz, C; Trenk, D; Valina, CM1
Angiolillo, DJ; Costigan, TM; DeRaad, R; Duvvuru, S; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF1
Alexopoulos, D; Damelou, A; Davlouros, P; Hahalis, G; Mavronasiou, E; Plakomyti, TE; Theodoropoulos, KC; Xanthopoulou, I1
Kiss, RG1
Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R1
Benjamin, MM; Donsky, MS; Filardo, G; Schussler, JM1
Fareed, J; Jeske, W; Thethi, I1
Ohman, EM; Roe, MT1
Dantzler, DM; Lynch, DR; Zhao, D1
Daly, RL; Dhutia, AJ; Ecob, R; Howgego, KE; Judge, HM; Mehra, S; Morton, AC; Storey, RF; Sumaya, W1
Goto, S; Tomiya, A1
Eslam, RB; Gremmel, T; Koppensteiner, R; Lang, IM; Panzer, S1
Maddox, TM1
Bernlochner, I; Braun, S; Kastrati, A; Mayer, K; Morath, T; Orban, M; Schömig, A; Schulz, S; Sibbing, D1
Bakhai, A; Barrett, A; Davies, A; Graham-Clarke, P; Schmitt, C; Sculpher, M1
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N1
Jung, DK; Kim, MH; Zhang, HZ1
Can, MM; Dinicolantonio, JJ; Goto, S; Serebruany, VL1
Clemmensen, P; Dridi, NP; Holmvang, L1
Aronow, WS2
Alexopoulos, D; Xanthopoulou, I1
Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S1
Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB1
Angiolillo, DJ; Rollini, F1
Kim, MH; Lee, DH; Lee, MS; Park, JS; Park, K; Park, TH; Seo, JM; Zhang, HZ1
Felix-Getzik, E; Sylvia, LM1
Alexopoulos, D; Davlouros, P; Mavronasiou, E; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I1
Kastrati, A; Martischnig, A; Mayer, K; Mehilli, J; Sarafoff, N; Sibbing, D; Wealer, J1
Bonello, L; Frere, C; Laine, M; Paganelli, F; Toesca, R1
Bertho, G; Dansette, PM; Hessani, A; Levent, D; Mansuy, D1
Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US1
Stiefelhagen, P1
Wang, H; Wang, WE; Wang, X; Zeng, C1
Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K1
Angiolillo, DJ; Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Jakubowski, JA; Jeong, YH; Kereiakes, DJ; Lasseter, KC; Logan, DK; Maa, JF; Nolin, TD; Ojeh, CK; Tantry, US; White, A1
Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S1
Franken, CC; Kaiser, AF; Krüger, JC; Mügge, A; Neubauer, H; Overbeck, K1
Coleman, CI; Limone, BL1
Eikelboom, J; Fitchett, D; Mazer, CD; Verma, S1
Oprea, AD; Popescu, WM1
Enar, R1
Göddertz, R1
de Lemos, JA; Diercks, DB; Hollander, JE; Holmes, DN; Kontos, MC; Mumma, BE; Saucedo, JF; Wiviott, S1
Baron, TH; Kamath, PS; McBane, RD1
DiNicolantonio, JJ; Serebruany, VL1
Huber, K; Lip, GY1
Angiolillo, DJ; Brown, PB; Erlinge, D; Foley, DP; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Luo, J; Moser, BA; Small, DS; Svensson, P; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C1
Bonello, L; Frère, C; Laine, M; Paganelli, F1
Apostolakis, S; Lip, GY; Shantsila, E1
Conde, D; Elissamburu, P; Lalor, N; Rodriguez, L; Trivi, M2
Christ, G; Francesconi, M; Grohs, K; Hafner, T; Podczeck-Schweighofer, A; Siller-Matula, JM; Wilhelm, E1
Pollack, CV1
Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ1
Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL1
Bray, PF; DeLa Cadena, RA; Garcia, AE; Kunapuli, SP; Liverani, E; Rico, MC1
Aradi, D; Baumstarck, K; Bessereau, J; Bonello, L; Camilleri, E; Camoin-Jau, L; Dignat-George, F; Fernandez, J; Laine, M; Maillard, L; Paganelli, F; Peyrol, M; Piot, C; Roubille, F1
Alessi, MC; Beguin, S; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Pons, C; Quilici, J1
Franklin, JM; Glynn, RJ; Patrick, AR; Schneeweiss, S; Weinstein, MC1
Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Collet, JP; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB1
Dinicolantonio, JJ; Norgard, NB1
Acosta, J; Benezet, J; Cubero Gómez, JM; Díaz DE LA Llera, LS; Fernández-Cisnal, A; Parejo, J; Rangel, D; Zafra, F1
Feldman, DN; Swaminathan, RV1
Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD1
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cuisset, T; Grosdidier, C; Lambert, M; Loosveld, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J1
Gross, L; Massberg, S; Orban, M; Sibbing, D1
Beigel, R; Elian, D; Fefer, P; Fink, N; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Rosenberg, N; Segev, A1
Aylward, PE; Sinhal, AR1
Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I1
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G1
Moertl, D; Steiner, S1
Angiolillo, DJ; Braun, OÖ; Costigan, TM; Duvvuru, S; Effron, MB; Ferreiro, JL; Jakubowski, JA; Kleiman, NS; Saucedo, JF; Sundseth, S; Varenhorst, C; Walker, JR; Winters, KJ1
Grove, EL; Würtz, M1
Chua, D; Nishi, C1
Chen, X; Gao, W; Jing, J; Li, N; Lu, Y; Parekha, HS; Qiu, Z; Ren, S; Song, L; Tian, F; Wang, X1
He, B; Kun, L; Liu, X; Wu, B1
Abbate, R; Antoniucci, D; Carrabba, N; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R1
Antman, EM; Braunwald, E; Cannon, CP; Giugliano, RP; Mogabgab, O; Sabatine, MS; Sloan, S; Wiviott, SD1
Angiolillo, DJ; Cardillo, TE; Diodati, JG; Effron, MB; Fisher, HN; French, JK; Fung, AY; Henneges, C; Saucedo, JF1
Curkovic, I; Egbring, M; Kullak-Ublick, GA1
Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD1
Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD1
Adsett, G; Jayasinghe, R; Markham, R1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD1
Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD1
Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M1
Meinertz, T1
Damman, P; Eriksson, P; Erlinge, D; James, SK; Koul, S; Lagerqvist, B; Varenhorst, C1
Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q1
Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V1
Brennan, T; Canestaro, WJ; Chaplin, D; Choudhry, NK; Desai, NR; Kyrychenko, P; Martell, LA; Matlin, OS1
Verheugt, FW1
Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD1
Clemmensen, P; Dridi, NP; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K; Stissing, T1
Dhillon, K; Dovlatova, N; Fox, SC; Glenn, JR; Heptinstall, S; White, AE1
Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I1
Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M1
Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ1
Balasubramaniam, K; Koshy, A; Noman, A; Zaman, AG1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C1
Ay, C; Badr Eslam, R; Eichelberger, B; Gremmel, T; Lang, IM; Panzer, S; Posch, F1
Gasparovic, H; Petricevic, M1
Alessi, MC; Bonnet, JL; Cuisset, T; Quilici, J1
Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK1
Hirschl, MM1
Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A1
Gupta, K; Singh, D; Vacek, JL1
Bohn, RL; Choudhry, NK; Daniel, GW; Gagne, JJ; Liu, J; Patrick, AR; Rassen, JA; Schneeweiss, S; Sridhar, G1
Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ1
Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Tantry, US1
Coons, JC; Harris, J; Schwier, N; Seybert, AL1
Christoph, M; Ibrahim, K; Jellinghaus, S; Kolschmann, S; Mues, C; Pfluecke, C; Quick, S; Schmeinck, S; Schmieder, K; Schoener, L; Steiding, K; Strasser, RH; Wunderlich, C1
Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J1
Sabouret, P; Taiel-Sartral, M1
Brener, SJ; El-Omar, M; Gibson, CM; Maehara, A; Mehran, R; Oldroyd, KG; Stone, GW; Witzenbichler, B; Xu, K1
Braun, D; Gershlick, AH; Hauschke, D; Ibrahim, T; Kastrati, A; Laugwitz, KL; Mayer, K; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schulz, S; Schunkert, H; Tölg, R1
Hartung, P; Hill, K; Schaefer, M; Schulze, A1
Delzor, F; Nanau, RM; Neuman, MG1
Antoniucci, D; De Luca, G; Marino, P; Parodi, G; Schaffer, A; Suryapranata, H; Verdoia, M1
Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; De Luca, G; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Ramazzotti, RN; Valenti, R1
Caldeira, D; Ferreira, JJ; Pinto, FJ1
Bouatou, Y; Gabrielli, A; Saudan, P1
Angiolillo, DJ; Cardillo, TE; Diodati, JG; Duvvuru, S; Effron, MB; Fisher, HN; Henneges, C; Jakubowski, JA; Lipkin, FR; Saucedo, JF; Sundseth, SS; Walker, JR1
Bernlochner, I; Braun, S; Hausleiter, J; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Morath, T; Schulz, S; Schunkert, H; Sibbing, D1
Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU1
Taylor, J1
Delemos, J; Peng, SA; Peterson, ED; Roe, MT; Sherwood, MW; Wang, TY; Wiviott, SD1
Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D1
Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H1
Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P1
Gislason, G; Sørensen, R1
Elosua, R; Marrugat, J; Vila, J2
Catalá-López, F1
Fortmann, SD; Serebruany, VL1
Abdel-Wahab, M; Anette Fiedler, K; Gershlick, AH; Hoppmann, P; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schneider, S; Schulz, S; Schunkert, H; Tölg, R1
Massberg, S; Sibbing, D1
Harrington, RA; Himmelmann, A; Steg, PG; Storey, RF; Wallentin, L1
De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P1
Bataille, V; Carrié, D; Garcia, C; Lhermusier, T; Lipinski, MJ; Mejean, S; Murat, G; Sié, P; Voisin, S1
Bolliger, D; Drews, S; Eckstein, F; Grapow, M; Kaiser, C; Matt, P; Reuthebuch, O1
Jelliffe, R1
Antoniucci, D; Migliorini, A; Valenti, R1
Takahashi, J1
Maloof, JA; Williams, MF1
Antman, EM; Braunwald, E; Montalescot, G; Murphy, SA; Udell, JA; Wiviott, SD1
Roe, MT; Sherwood, MW1
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Vanassche, T; Weitz, JI1
Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Gurbel, PA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Sritara, P; White, HD; Zamoryakhin, D1
Angiolillo, DJ; Bergmeijer, TO; Brown, PB; Duvvuru, S; Erlinge, D; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Moser, BA; Small, D; Sundseth, S; Svensson, P; Tantry, US; ten Berg, JM; Walker, JR; Winters, KJ1
Abtan, J; Anzaha, G; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Charland, SL; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Stanek, EJ1
Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R1
Calcagno, S; Sardella, G1
Aradi, D; Komócsi, A1
Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z1
Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y1
Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X1
Christ, G; Dechant, C; Delle-Karth, G; Francesconi, M; Grohs, K; Gruber, C; Jilma, B; Podczeck-Schweighofer, A; Siller-Matula, JM1
Bernlochner, I; Braun, S; Hadamitzky, M; Hausleiter, J; Hoppmann, P; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Mehilli, J; Morath, T; Orban, M; Schulz, S; Schunkert, H; Sibbing, D; Tiroch, K1
Fauchère, I; Schreiber, P; Wyss, C1
Ahn, JH; Gurbel, P; Jeong, YH; Kim, KH; Tantry, US1
Nakamura, M; Saito, S1
Crivera, C; Dea, K; Fields, LE; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, JR1
Vengoechea, F1
Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H1
Biocina, B; Boban, M; Ivancan, V; Konosic, S; Mihaljevic, MZ; Petricevic, M; Samardzic, J1
Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM1
Chieffo, A; Colombo, A1
Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW1
Huynh, K1
Bae, JP; Candrilli, SD; Drenning, D; Fortenberry, J; Jakubowski, JA; Meyers, JL1
Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG1
Anderson, JL; Goto, S; Huo, Y; Jeong, YH; Levine, GN; Mega, JL; Smith, SC; Taubert, K1
Arntz, HR; Diller, F; Mark, B; Mochmann, HC; Montalescot, G; Thiele, H; Zahn, R; Zeymer, U1
Lhermusier, T; Waksman, R1
Assinger, A; Kral, JB; Scharbert, G; Schrottmaier, WC; Weber, T; Wetzel, L1
Jiang, M; You, JH1
Bultas, J1
Baker, N; Bliden, KP; Chen, F; Escarcega, RO; Gurbel, PA; Lhermusier, T; Lipinski, MJ; Magalhaes, MA; Minha, S; Ota, H; Pendyala, L; Tantry, US; Tian, W; Torguson, R; Waksman, R1
Bolliger, D; Drews, S; Eckstein, F; Kaiser, C; Matt, P1
Helft, G1
Calıskan, A; Demirtas, S; Guclu, O; Kaplan, I; Karahan, O; Tezcan, O; Yavuz, C; Yazıcı, S1
Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S1
Keaney, JF1
Guyatt, G; Spencer, FA1
Steg, PG; Wiviott, SD1
Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S1
Chen, L; Liu, D; Liu, Y; Tao, Z; Xia, G; Zhi, S1
Bode, C; Cohen, M; Fox, K; Gibson, CM; Halperin, J; Husted, S; Lip, GY; Mehran, R; Peterson, E; van Eickels, M; Verheugt, F; Wildgoose, P1
Kereiakes, DJ; Mauri, L; Yeh, RW1
Sipahi, I1
Dohan, JL1
Marrs, JC1
Jeger, R; Kaiser, C; Pfisterer, M1
Tomoda, H1
Angoulvant, D; Angoulvant, TB; Fauchier, L1
Liakishev, AA1
Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY1
Lozano, I; Rondan, J; Segovia, E; Vegas, JM1
Montalescot, G; Zeymer, U1
Alexopoulos, D; Bhatt, DL; Hamm, CW; Steg, PG; Stone, GW1
Ahsan, CH; Ali, ML; Amin, MN; Chowdhury, MZ; Haq, MM; Karim, MR; Khan, SR; Mansur, M; Millat, MH; Rashid, MA1
Bangalore, S; Bavishi, C; Messerli, FH; Panwar, S1
Ofosu, FA1
Desch, S; Eitel, I; Empen, K; Ferenc, M; Fuernau, G; Hambrecht, R; Hausleiter, J; Hennersdorf, M; Limbourg, T; Neumann, FJ; Olbrich, HG; Orban, M; Pöss, J; Richardt, G; Schneider, S; Schuler, G; Thiele, H; Werdan, K; Zeymer, U1
Angiolillo, DJ; Franchi, F1
Fawcett, JP; Gu, J; Liu, M; Meng, X; Su, C; Wang, H; Xu, X; Yang, Y; Yang, Z; Zhao, X1
Parker, WA; Storey, RF1
Ji, JZ; Jia, YM; Tai, T; Xie, HG1
Ding, Y; Gong, Y; Lai, X; Li, X; Li, Y; Liu, C; Liu, X; Liu, Y; Sun, H; Wei, H; Xia, Y; Zhan, Y; Zhang, H; Zhang, Y; Zhong, D; Zhu, X; Zhu, Y1
Galford, KF; Jose, AM1
Gong, Y; He, Y; Lai, X; Li, YG; Liu, X; Liu, Y; Sun, H; Yan, X; Zhang, EY; Zhang, L1

Reviews

202 review(s) available for ticlopidine and thiophenes

ArticleYear
[Mechanism of platelet aggregation inhibition].
    Rinsho byori. The Japanese journal of clinical pathology, 1979, Volume: Suppl 40

    Topics: Adenylyl Cyclases; Animals; Blood Platelets; Cyclic AMP; Depression, Chemical; Phosphodiesterase Inhibitors; Platelet Aggregation; Prostaglandins; Pyridines; Rats; Thiophenes; Ticlopidine

1979
Pharmacology of the interaction between platelets and vessel wall.
    Clinics in haematology, 1986, Volume: 15, Issue:2

    Topics: Animals; Aspirin; Blood Platelets; Blood Vessels; Dextrans; Diltiazem; Dipyridamole; Epoprostenol; Humans; Imidazoles; Ketanserin; Piperidines; Pyrazoles; Pyrazolones; Sulfinpyrazone; Sulfonamides; Thiophenes; Ticlopidine

1986
[Platelet function inhibitors in peripheral arteriopathies].
    Recenti progressi in medicina, 1986, Volume: 77, Issue:4

    Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases

1986
[Thrombosis in various diseases: myocardial infarct].
    Nihon rinsho. Japanese journal of clinical medicine, 1986, Volume: 44, Issue:5

    Topics: Angioplasty, Balloon; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine

1986
Antiplatelet drugs in the management of patients with thrombotic disorders.
    Seminars in thrombosis and hemostasis, 1986, Volume: 12, Issue:2

    Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets; Catheterization; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Glomerulonephritis; Humans; Sulfinpyrazone; Suloctidil; Thiophenes; Thrombophlebitis; Thrombosis; Ticlopidine; Vascular Diseases; Vascular Surgical Procedures

1986
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
    Circulation, 1986, Volume: 73, Issue:2

    Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Female; Glomerulonephritis; Graft Occlusion, Vascular; Heart Valve Prosthesis; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Postoperative Complications; Random Allocation; Sulfinpyrazone; Thiophenes; Ticlopidine

1986
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Humans; Intermittent Claudication; Leg; Platelet Aggregation; Platelet Factor 4; Suloctidil; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine

1984
[Role of antiaggregant platelet drugs in thromboembolism].
    Giornale italiano di cardiologia, 1981, Volume: 11, Issue:8

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anti-Bacterial Agents; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Humans; Mitral Valve; Platelet Aggregation; Platelet Function Tests; Pyridines; Pyridinolcarbamate; Random Allocation; Sulfinpyrazone; Suloctidil; Thiophenes; Thromboembolism; Ticlopidine

1981
Cyclic nucleotides, prostaglandins, and ischemic heart disease.
    Advances in cyclic nucleotide and protein phosphorylation research, 1984, Volume: 17

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arteriosclerosis; Coronary Disease; Diet, Atherogenic; Myocardial Contraction; Myocardial Infarction; Nucleotides, Cyclic; Prostaglandins; Rabbits; Thiophenes; Thromboxane A2; Ticlopidine

1984
[Platelet anti-aggregant drugs and ischemic cardiopathy: evaluation of the effect on platelet aggregation and on antithrombin III].
    Bollettino della Societa italiana di cardiologia, 1981, Volume: 26, Issue:8

    Topics: Adult; Anticoagulants; Antithrombin III; Arrhythmias, Cardiac; Clofibrate; Dipyridamole; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation; Pyridines; Sulfinpyrazone; Suloctidil; Thiophenes; Ticlopidine

1981
[Pharmacology of anti-platelet agents].
    Journal des maladies vasculaires, 1983, Volume: 8, Issue:1

    Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Dipyridamole; Epoprostenol; Female; Fibrinolytic Agents; Humans; In Vitro Techniques; Intestinal Absorption; Kinetics; Male; Papio; Platelet Aggregation; Prostaglandin Antagonists; Rabbits; Sulfinpyrazone; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine

1983
Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.
    Thrombosis research. Supplement, 1983, Volume: 4

    Topics: Adenosine Diphosphate; Animals; Blood Coagulation; Blood Platelets; Collagen; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Kinetics; Platelet Aggregation; Rats; Thiophenes; Ticlopidine; Time Factors

1983
The mechanisms of action of ticlopidine.
    Thrombosis research. Supplement, 1983, Volume: 4

    Topics: Adenosine Diphosphate; Animals; Fibrinolytic Agents; Humans; In Vitro Techniques; Malondialdehyde; Platelet Aggregation; Prostaglandins; Thiophenes; Ticlopidine; Time Factors

1983
Overview: pharmacology of ticlopidine.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Animals; Anticoagulants; Bleeding Time; Blood Vessels; Humans; Kinetics; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine

1984
Overview: clinical experiences with ticlopidine.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anemia, Sickle Cell; Anticoagulants; Arterial Occlusive Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypass; Extracorporeal Circulation; Humans; Renal Dialysis; Retinal Diseases; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine

1984
Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Biotransformation; Dose-Response Relationship, Drug; Humans; Kinetics; Platelet Aggregation; Thiophenes; Ticlopidine

1984
[Platelet aggregation and antiaggregant drugs].
    Recenti progressi in medicina, 1982, Volume: 73, Issue:5

    Topics: Dipyridamole; Humans; Papaverine; Platelet Aggregation; Prostaglandins; Theophylline; Thiophenes; Thromboxane A2; Ticlopidine; Verapamil

1982
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
    Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:2

    Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic; Clopidogrel; Collagen; Drug Evaluation, Preclinical; Drug Synergism; Fibrinolytic Agents; Hemostasis; Humans; Male; Membrane Proteins; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombin; Thrombosis; Ticlopidine

2005
Aspirin and clopidogrel resistance: consideration and management.
    Journal of interventional cardiology, 2006, Volume: 19, Issue:5

    Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine

2006
Prasugrel.
    Expert opinion on investigational drugs, 2006, Volume: 15, Issue:12

    Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Collagen; Coronary Disease; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2006
Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1

    Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine

2007
Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
    Thrombosis and haemostasis, 2007, Volume: 97, Issue:3

    Topics: Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drugs, Investigational; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2007
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
    Journal of cardiovascular pharmacology and therapeutics, 2007, Volume: 12, Issue:3

    Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Bayes Theorem; Clinical Trials, Phase I as Topic; Clopidogrel; Databases, Factual; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome

2007
ADP receptor antagonism: what's in the pipeline?
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:6

    Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2007
Will prasugrel supersede clopidogrel for acute coronary syndromes?
    The Medical journal of Australia, 2008, Apr-07, Volume: 188, Issue:7

    Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine

2008
Prasugrel: a novel antiplatelet agent.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11

    Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine

2008
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
    Journal of interventional cardiology, 2008, Volume: 21, Issue:4

    Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine

2008
Antiplatelet drugs in cardiological practice: established strategies and new developments.
    Vascular health and risk management, 2008, Volume: 4, Issue:3

    Topics: Atherosclerosis; Clopidogrel; Drug-Eluting Stents; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thromboxane; Signal Transduction; Thiophenes; Thrombosis; Ticlopidine

2008
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Cardiology clinics, 2008, Volume: 26, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine

2008
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
    Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12

    Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2008
Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?
    American family physician, 2008, Dec-01, Volume: 78, Issue:11

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome

2008
Prasugrel development - claims and achievements.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Discovery; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome

2009
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
    Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:1

    Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine

2009
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
    Critical pathways in cardiology, 2009, Volume: 8, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome

2009
Response variability and the role of platelet function testing.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2009
New antiplatelet drugs: beyond aspirin and clopidogrel.
    International journal of clinical practice, 2009, Volume: 63, Issue:5

    Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine

2009
Critical review of prasugrel for formulary decision makers.
    Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Formularies, Hospital as Topic; Humans; Managed Care Programs; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Thiophenes; Ticlopidine

2009
Prasugrel for the treatment of patients with acute coronary syndrome.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome

2009
Management of patients with high gastrointestinal risk on antiplatelet therapy.
    Gastroenterology clinics of North America, 2009, Volume: 38, Issue:2

    Topics: Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Peptic Ulcer Hemorrhage; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Risk Factors; Thiophenes; Ticlopidine

2009
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
    Future cardiology, 2009, Volume: 5, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine

2009
Bedside evaluation of thienopyridine antiplatelet therapy.
    Circulation, 2009, May-19, Volume: 119, Issue:19

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Humans; Mass Screening; Myocardial Infarction; Nephelometry and Turbidimetry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombelastography; Ticlopidine; United States

2009
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Diabetes Complications; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stents; Thiophenes; Ticlopidine; Treatment Outcome

2009
Review of prasugrel for the secondary prevention of atherothrombosis.
    Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:5

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Thrombosis; Ticlopidine

2009
Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?
    Fundamental & clinical pharmacology, 2009, Volume: 23, Issue:4

    Topics: Animals; Aspirin; Clopidogrel; Colonic Neoplasms; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2009
Diabetes and acute coronary syndromes.
    Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine

2009
[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
    Pharmazie in unserer Zeit, 2009, Volume: 38, Issue:4

    Topics: Animals; Biotransformation; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine

2009
[Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].
    Pharmazie in unserer Zeit, 2009, Volume: 38, Issue:4

    Topics: Administration, Oral; Animals; Aspirin; Clopidogrel; Dipyridamole; Humans; Patents as Topic; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
    Reviews in cardiovascular medicine, 2009,Spring, Volume: 10, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome

2009
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.
    European heart journal, 2009, Volume: 30, Issue:16

    Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine

2009
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
    Platelets, 2009, Volume: 20, Issue:5

    Topics: Adult; Clopidogrel; Coronary Artery Disease; Data Collection; Female; Humans; Kinetics; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Young Adult

2009
Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Drugs, 2009, Aug-20, Volume: 69, Issue:12

    Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Tissue Distribution; Young Adult

2009
Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.
    The American journal of cardiology, 2009, Sep-07, Volume: 104, Issue:5 Suppl

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
    Lancet (London, England), 2009, Sep-19, Volume: 374, Issue:9694

    Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome

2009
Prasugrel (Effient) vs. clopidogrel (Plavix).
    The Medical letter on drugs and therapeutics, 2009, Sep-07, Volume: 51, Issue:1320

    Topics: Animals; Clopidogrel; Drug Approval; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; United States

2009
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
    Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine

2009
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Vascular health and risk management, 2009, Volume: 5

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2009
Advances in antiplatelet treatment for acute coronary syndromes.
    Heart (British Cardiac Society), 2010, Volume: 96, Issue:9

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2010
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine

2009
Prasugrel: a critical comparison with clopidogrel.
    Pharmacotherapy, 2009, Volume: 29, Issue:12

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Drug Inverse Agonism; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States

2009
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:2

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine

2010
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9 Suppl 1

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine

2009
Prasugrel: Clinical development and therapeutic application.
    Advances in therapy, 2009, Volume: 26, Issue:11

    Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Thrombosis; Ticlopidine

2009
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
    British journal of pharmacology, 2010, Feb-01, Volume: 159, Issue:3

    Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor

2010
State of the art of new P2Y12 antagonists.
    Internal and emergency medicine, 2010, Volume: 5, Issue:5

    Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine

2010
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
    QJM : monthly journal of the Association of Physicians, 2010, Volume: 103, Issue:6

    Topics: Clopidogrel; Drug Evaluation, Preclinical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine

2010
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
    Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:6

    Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine

2010
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Kidney Failure, Chronic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2010
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.
    Annals of the Academy of Medicine, Singapore, 2010, Volume: 39, Issue:3

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2010
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
    Current opinion in cardiology, 2010, Volume: 25, Issue:4

    Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine

2010
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
    Atherosclerosis, 2010, Volume: 212, Issue:2

    Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Glycoproteins; Humans; Models, Biological; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thromboplastin; Thrombosis; Ticlopidine

2010
[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].
    Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:2

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome

2010
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
    Current opinion in cardiology, 2010, Volume: 25, Issue:4

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2010
Acute coronary syndrome in the patient with diabetes: is the management different?
    Current cardiology reports, 2010, Volume: 12, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine

2010
Implementing genotype-guided antithrombotic therapy.
    Future cardiology, 2010, Volume: 6, Issue:3

    Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Genetic Privacy; Genotype; Health Policy; Humans; Mixed Function Oxygenases; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K Epoxide Reductases; Warfarin

2010
The year in interventional cardiology.
    Journal of the American College of Cardiology, 2010, May-18, Volume: 55, Issue:20

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Foramen Ovale, Patent; Hospital Mortality; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Radiology, Interventional; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome

2010
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
    Hospital practice (1995), 2010, Volume: 38, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2010
What goes into a major acute coronary syndrome trial and what will future trials look like?
    Current cardiology reports, 2010, Volume: 12, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom

2010
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
    Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Economic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quality of Life; Quality-Adjusted Life Years; Risk Assessment; Thiophenes; Ticlopidine; United Kingdom

2010
New antithrombotic agents--insights from clinical trials.
    Nature reviews. Cardiology, 2010, Volume: 7, Issue:9

    Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine

2010
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
    Kardiologiia, 2010, Volume: 50, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration

2010
Prasugrel.
    Circulation, 2010, Jul-27, Volume: 122, Issue:4

    Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2010
[Platelet inhibition with prasugrel].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:31-32

    Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogrel; Coronary Artery Disease; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine

2010
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
    Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine

2010
Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery.
    The Annals of thoracic surgery, 2010, Volume: 90, Issue:3

    Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticlopidine

2010
A comparison of the metabolism of clopidogrel and prasugrel.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:11

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Thiophenes; Thrombosis; Ticlopidine

2010
Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.
    Critical care nurse, 2010, Volume: 30, Issue:5

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2010
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
    Current drug metabolism, 2010, Volume: 11, Issue:8

    Topics: Animals; Biological Availability; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2010
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.
    Vascular health and risk management, 2010, Oct-05, Volume: 6

    Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Myocardial Revascularization; Perioperative Care; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2010
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
    Blood, 2011, Feb-17, Volume: 117, Issue:7

    Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine

2011
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
    Circulation, 2010, Dec-14, Volume: 122, Issue:24

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine

2010
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:4

    Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Thiophenes; Ticlopidine; Treatment Outcome; United States

2010
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
    The American journal of gastroenterology, 2010, Volume: 105, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine

2010
Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:1

    Topics: Animals; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2011
[New approaches and indications for the analysis of platelet function in cardiology].
    Hamostaseologie, 2011, May-02, Volume: 31, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2011
[Novel agents in antiplatelet therapy].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine

2010
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Standard of Care; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2011
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
    Journal of cardiovascular pharmacology, 2011, Volume: 57, Issue:3

    Topics: Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors

2011
Antiplatelet therapy in the perioperative period.
    Acta anaesthesiologica Belgica, 2010, Volume: 61, Issue:3

    Topics: Aspirin; Clopidogrel; Humans; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2010
[Coronary heart disease - what is of importance after coronary intervention?].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:5

    Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine

2011
Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.
    Postgraduate medicine, 2011, Volume: 123, Issue:1

    Topics: Area Under Curve; Clopidogrel; Drug Interactions; Half-Life; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2011
[Current options to manage clopidogrel poor responsiveness].
    Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2010
Triple therapy in hospitalized patients: facts and controversies.
    Journal of hospital medicine, 2011, Volume: 6, Issue:9

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hospitalization; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin

2011
Is prasugrel more effective than clopidogrel at preventing future cardiac events?
    JAAPA : official journal of the American Academy of Physician Assistants, 2011, Volume: 24, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2011
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15

    Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2011
Triple therapy: boon or bane for high-risk CV patients?
    The Journal of family practice, 2011, Volume: 60, Issue:4

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Warfarin

2011
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
    Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1

    Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine

2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
    Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1

    Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2011
[Myocardial infarction: Role of new antiplatelet agents].
    Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6

    Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors

2011
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
    QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine

2011
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
    Recenti progressi in medicina, 2011, Volume: 102, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine

2011
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
    Current atherosclerosis reports, 2011, Volume: 13, Issue:4

    Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine

2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
    Current cardiology reports, 2011, Volume: 13, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine

2011
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
    European heart journal, 2011, Volume: 32, Issue:18

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2011
Ticagrelor for acute coronary syndrome?
    Drug and therapeutics bulletin, 2011, Volume: 49, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2011
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
    Clinical therapeutics, 2011, Volume: 33, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2011
Prasugrel resistance: fact or fiction.
    Platelets, 2012, Volume: 23, Issue:2

    Topics: Blood Platelets; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2012
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
    Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:15-16

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine

2011
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.
    Current cardiology reports, 2011, Volume: 13, Issue:5

    Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Female; Genetic Association Studies; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2011
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
    Current medical research and opinion, 2011, Volume: 27, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2011
Antiplatelet options for secondary prevention in acute coronary syndromes.
    Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine

2011
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
    Journal of the American College of Cardiology, 2011, Nov-22, Volume: 58, Issue:22

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia

2011
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
    Current medical research and opinion, 2012, Volume: 28, Issue:2

    Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2012
P2Y12 platelet inhibition in clinical practice.
    Journal of thrombosis and thrombolysis, 2012, Volume: 33, Issue:2

    Topics: Adenosine; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine

2012
Platelet-mediated thrombosis and drug-eluting stents.
    Circulation. Cardiovascular interventions, 2011, Dec-01, Volume: 4, Issue:6

    Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Equipment Design; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine

2011
Unstable angina and non-ST elevation myocardial infarction.
    American journal of respiratory and critical care medicine, 2012, May-01, Volume: 185, Issue:9

    Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2012
A comprehensive comparative review of adenosine diphosphate receptor antagonists.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
InforMatrix: ADP antagonists in acute coronary syndromes.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Information Services; Drugs, Generic; Evidence-Based Medicine; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO.
    International journal of cardiology, 2012, Jul-12, Volume: 158, Issue:2

    Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2012
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2

    Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticlopidine

2012
Advances in antiplatelet therapy for acute coronary syndromes.
    Postgraduate medical journal, 2012, Volume: 88, Issue:1041

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
Acute coronary syndromes: identifying the appropriate patient for prasugrel.
    Postgraduate medicine, 2012, Volume: 124, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Secondary Prevention; Thiophenes; Ticlopidine

2012
Current antiplatelet options for NSTE-ACS patients.
    QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
    Clinical pharmacokinetics, 2012, Jul-01, Volume: 51, Issue:7

    Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2012
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome

2013
[New antithrombotic drugs].
    Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:7

    Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin

2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin

2012
Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Hospital practice (1995), 2012, Volume: 40, Issue:2

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2012
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
[Platelet function: new drugs, new assays : possible impacts on operative medicine?].
    Der Anaesthesist, 2012, Volume: 61, Issue:6

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Predictive Value of Tests; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2012
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
    Expert review of clinical pharmacology, 2012, Volume: 5, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2012
Development and clinical use of prasugrel and ticagrelor.
    Current pharmaceutical design, 2012, Volume: 18, Issue:33

    Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
    Current pharmaceutical design, 2012, Volume: 18, Issue:33

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
    Coronary artery disease, 2012, Volume: 23, Issue:6

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin

2012
A brief review of the past and future of platelet P2Y12 antagonist.
    Coronary artery disease, 2012, Volume: 23, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2012
Antiplatelet therapy beyond 2012: role of personalized medicine.
    Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:6

    Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2012
Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:12

    Topics: Clopidogrel; Costs and Cost Analysis; Drug Interactions; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2012
[Comparative antiplatelet efficacy of prasugrel and high-dose clopidogrel in patients with coronary heart disease including acute coronary syndrome].
    Kardiologiia, 2012, Volume: 52, Issue:3

    Topics: Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2012
Clopidogrel in coronary artery disease: update 2012.
    Advances in cardiology, 2012, Volume: 47

    Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
Genetic considerations.
    Advances in cardiology, 2012, Volume: 47

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Genome-Wide Association Study; Genotype; Humans; Liver; Pharmacogenetics; Phenotype; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2012
Advances in the monitoring of anti-P2Y12 therapy.
    Platelets, 2012, Volume: 23, Issue:7

    Topics: Adenosine; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine

2012
Thienopyridines and other ADP-receptor antagonists.
    Handbook of experimental pharmacology, 2012, Issue:210

    Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine

2012
New anti-platelet agents: the end of resistance?
    Thrombosis research, 2012, Volume: 130 Suppl 1

    Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2012
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).
    Seminars in thrombosis and hemostasis, 2012, Volume: 38, Issue:8

    Topics: Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purpura, Thrombotic Thrombocytopenic; Thienopyridines; Thiophenes; Ticlopidine

2012
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
    Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:3

    Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2013
[Novel agents for antithrombotic therapy in cardiology].
    Orvosi hetilap, 2012, Dec-23, Volume: 153, Issue:51

    Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine

2012
Metabolic differences of current thienopyridine antiplatelet agents.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Inactivation, Metabolic; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine

2013
Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Cardiovascular drugs and therapy, 2013, Volume: 27, Issue:3

    Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
    Postgraduate medicine, 2013, Volume: 125, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2013
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
    European heart journal, 2013, Volume: 34, Issue:23

    Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin

2013
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
    Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2014
Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:9

    Topics: Adenosine; Blood Loss, Surgical; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2013
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
    Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:4

    Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Surgical Procedures, Operative; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2013, Volume: 41, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2013
New anticoagulant and antiplatelet agents: a primer for the gastroenterologist.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:2

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cholangiopancreatography, Endoscopic Retrograde; Clopidogrel; Dabigatran; Drug Interactions; Fondaparinux; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Polysaccharides; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
Pharmacokinetic considerations for antithrombotic therapies in stroke.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:10

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Tetrazoles; Thiophenes; Thrombin; Ticlopidine; Vitamin K

2013
Use of antiplatelet drugs in the treatment of acute coronary syndromes.
    Cardiovascular & hematological disorders drug targets, 2013, Volume: 13, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2013
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
    Postgraduate medicine, 2013, Volume: 125, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2013
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
    Clinical therapeutics, 2013, Volume: 35, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2013
Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.
    Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:8

    Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions].
    Ugeskrift for laeger, 2013, Sep-09, Volume: 175, Issue:37

    Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine

2013
New antiplatelet agents for cardiovascular disease.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Nov-05, Volume: 185, Issue:16

    Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
[Thrombocyte aggregation inhibitors: what are the risks?].
    Praxis, 2013, Oct-02, Volume: 102, Issue:20

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine

2013
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
    The journal of trauma and acute care surgery, 2013, Volume: 75, Issue:3

    Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin

2013
Use of antiplatelet agents in patients with atherosclerotic disease.
    Postgraduate medicine, 2013, Volume: 125, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2013
Dual antiplatelet therapy -- management in general practice.
    Australian family physician, 2013, Volume: 42, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2013
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
    Stroke, 2014, Volume: 45, Issue:2

    Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases

2014
[Differentiated antiplatelet therapy for acute coronary syndromes].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2014
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
    Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin

2014
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
    The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine

2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Atherosclerosis, 2014, Volume: 233, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine

2014
Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:6

    Topics: Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Reduction Behavior; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction.
    Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:4

    Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
New antiplatelet agents in the treatment of acute coronary syndromes.
    Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Efficacy and safety of prasugrel in acute coronary syndrome patients.
    Clinical biochemistry, 2014, Volume: 47, Issue:7-8

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2014
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:4

    Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine

2014
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
    Revue medicale suisse, 2014, Feb-26, Volume: 10, Issue:419

    Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2014
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:2

    Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Role of phenotypic and genetic testing in managing clopidogrel therapy.
    Blood, 2014, Jul-31, Volume: 124, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Genetic Testing; Humans; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine

2014
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
    Praxis, 2014, Sep-03, Volume: 103, Issue:18

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine

2014
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
    Hospital practice (1995), 2014, Volume: 42, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine

2014
Prasugrel hydrochloride for the treatment of acute coronary syndromes.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4

    Topics: Acute Coronary Syndrome; Animals; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2015
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine

2015
[Anticoagulant therapy in secondary prevention of coronary events].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:12

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin

2014
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
    The American journal of cardiology, 2015, Mar-15, Volume: 115, Issue:6

    Topics: Adenosine; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Research Design; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2015
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
    Lancet (London, England), 2015, Jul-18, Volume: 386, Issue:9990

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome

2015
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
    The American journal of cardiology, 2015, Aug-01, Volume: 116, Issue:3

    Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine

2015
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
    American heart journal, 2015, Volume: 170, Issue:1

    Topics: Adenosine; Clopidogrel; Early Medical Intervention; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome

2015
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
    The American journal of cardiology, 2015, Sep-01, Volume: 116, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2015
Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China.
    Journal of cardiovascular pharmacology, 2017, Volume: 70, Issue:6

    Topics: Acute Coronary Syndrome; China; Clopidogrel; Drug Discovery; Drug Resistance; Humans; Phenylacetates; Platelet Aggregation Inhibitors; Prodrugs; Thiophenes; Ticlopidine

2017

Trials

162 trial(s) available for ticlopidine and thiophenes

ArticleYear
[Platelet function inhibitors in peripheral arteriopathies].
    Recenti progressi in medicina, 1986, Volume: 77, Issue:4

    Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases

1986
Therapy of atherosclerotic arteriopathy of lower limbs. Aspects and results.
    Angiology, 1985, Volume: 36, Issue:10

    Topics: Acute Disease; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Glycosaminoglycans; Heparin; Humans; Injections, Subcutaneous; Leg; Pentoxifylline; Streptokinase; Thiophenes; Ticlopidine; Urokinase-Type Plasminogen Activator; Vasodilator Agents

1985
Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon.
    Angiology, 1986, Volume: 37, Issue:8

    Topics: Adult; Aged; Anticoagulants; Clinical Trials as Topic; Double-Blind Method; Drug Eruptions; Female; Humans; Male; Middle Aged; Placebos; Random Allocation; Raynaud Disease; Thiophenes; Ticlopidine

1986
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
    Circulation, 1986, Volume: 73, Issue:2

    Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Female; Glomerulonephritis; Graft Occlusion, Vascular; Heart Valve Prosthesis; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Postoperative Complications; Random Allocation; Sulfinpyrazone; Thiophenes; Ticlopidine

1986
Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time.
    Blood, 1986, Volume: 67, Issue:4

    Topics: Adolescent; Adult; Aged; Aspirin; Bleeding Time; Clinical Trials as Topic; Deamino Arginine Vasopressin; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Platelet Function Tests; Random Allocation; Thiophenes; Thrombocytopenia; Ticlopidine; von Willebrand Factor

1986
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
    European heart journal, 1986, Volume: 7, Issue:1

    Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Graft Occlusion, Vascular; Heparin; Humans; Platelet Aggregation; Saphenous Vein; Sulfinpyrazone; Thiophenes; Ticlopidine

1986
Does placebo improve indexes of effort-induced myocardial ischemia? An objective study in 150 patients with chronic stable angina pectoris.
    The American journal of cardiology, 1986, Apr-15, Volume: 57, Issue:11

    Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Electrocardiography; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Physical Exertion; Placebos; Thiophenes; Ticlopidine

1986
Influence on lipoprotein metabolism of the platelet inhibitory drug ticlopidine.
    Atherosclerosis, 1986, Volume: 59, Issue:3

    Topics: Adult; Aged; Angina Pectoris; Arteriosclerosis; Clinical Trials as Topic; Double-Blind Method; Humans; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Thiophenes; Ticlopidine

1986
Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis.
    Artificial organs, 1985, Volume: 9, Issue:1

    Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind Method; Graft Occlusion, Vascular; Humans; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine

1985
Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion.
    European heart journal, 1985, Volume: 6, Issue:2

    Topics: Acenocoumarol; Anticoagulants; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Graft Occlusion, Vascular; Humans; Middle Aged; Postoperative Complications; Thiophenes; Ticlopidine

1985
Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis.
    Scandinavian journal of urology and nephrology, 1985, Volume: 19, Issue:1

    Topics: Adult; Aged; Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Postoperative Complications; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine

1985
The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial.
    Thrombosis and haemostasis, 1985, Jun-24, Volume: 53, Issue:3

    Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Blood Platelets; Clinical Trials as Topic; Collagen; Double-Blind Method; Female; Fibrinolysis; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Placebos; Platelet Aggregation; Serotonin; Thiophenes; Ticlopidine

1985
Effects of ticlopidine of platelet function in men with stable angina pectoris.
    Thrombosis and haemostasis, 1985, Dec-17, Volume: 54, Issue:4

    Topics: Adenosine Diphosphate; Adult; Aged; Angina Pectoris; Blood Platelets; Clinical Trials as Topic; Collagen; Double-Blind Method; Epinephrine; Epoprostenol; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Ticlopidine

1985
Blood lipid profile in healthy subjects treated with ticlopidine.
    Atherosclerosis, 1985, Volume: 58, Issue:1-3

    Topics: Adult; Aged; Anticoagulants; Arteriosclerosis; Blood Platelets; Double-Blind Method; Drug Evaluation; Female; Humans; Lipids; Male; Middle Aged; Thiophenes; Ticlopidine

1985
Effects of ticlopidine on blood fibrinogen and blood viscosity in peripheral atherosclerotic disease.
    Arzneimittel-Forschung, 1985, Volume: 35, Issue:12

    Topics: Aged; Arteriosclerosis; Blood Coagulation; Blood Platelets; Blood Viscosity; Female; Fibrinogen; Humans; Locomotion; Male; Middle Aged; Nicotinic Acids; Thiophenes; Ticlopidine

1985
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Humans; Intermittent Claudication; Leg; Platelet Aggregation; Platelet Factor 4; Suloctidil; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine

1984
Effects of platelet inhibition on myocardial ischaemia.
    Lancet (London, England), 1982, Oct-02, Volume: 2, Issue:8301

    Topics: Angina Pectoris; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Disease; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Female; Hemodynamics; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Thiophenes; Ticlopidine

1982
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
    Nederlands tijdschrift voor geneeskunde, 1983, Apr-16, Volume: 127, Issue:16

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Hypolipidemic Agents; Myocardial Infarction; Patient Care Planning; Platelet Aggregation; Recurrence; Risk; Sulfinpyrazone; Thiophenes; Ticlopidine

1983
Effects of ticlopidine on platelet function and blood coagulation.
    Thrombosis and haemostasis, 1982, Oct-29, Volume: 48, Issue:2

    Topics: Adult; Aged; Arteriosclerosis; beta-Thromboglobulin; Blood Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Male; Malondialdehyde; Middle Aged; Partial Thromboplastin Time; Platelet Aggregation; Platelet Function Tests; Prothrombin Time; Thiophenes; Ticlopidine

1982
Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study.
    Haemostasis, 1983, Volume: 13, Issue:5

    Topics: Adenosine Diphosphate; Adult; Aged; beta-Thromboglobulin; Bleeding Time; Blood Platelets; Collagen; Epoprostenol; Humans; Male; Middle Aged; Platelet Aggregation; Prostaglandin D2; Prostaglandins D; Thiophenes; Thromboxane B2; Ticlopidine

1983
Failure of ticlopidine to inhibit deposition of indium-111-labeled platelets on Dacron prosthetic surfaces in humans.
    Circulation, 1984, Volume: 69, Issue:4

    Topics: Adult; Aged; Aorta; Bleeding Time; Blood Platelets; Blood Vessel Prosthesis; Clinical Trials as Topic; Humans; Indium; Male; Middle Aged; Placebos; Platelet Adhesiveness; Polyethylene Terephthalates; Radioisotopes; Radionuclide Imaging; Thiophenes; Ticlopidine

1984
[The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
    La Clinica terapeutica, 1983, Feb-15, Volume: 104, Issue:3

    Topics: Aged; Anticoagulants; Clinical Trials as Topic; Drug Evaluation; Humans; Middle Aged; Platelet Aggregation; Thiophenes; Ticlopidine

1983
Clinical trials of an antiplatelet agent, ticlopidine, in diabetes mellitus.
    Current medical research and opinion, 1983, Volume: 8, Issue:7

    Topics: Adult; Anticoagulants; Clinical Trials as Topic; Diabetic Angiopathies; Echocardiography; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Platelet Aggregation; Thiophenes; Ticlopidine

1983
[Effect of ticlopidine on peripheral obliterating arteriopathy].
    Deutsche medizinische Wochenschrift (1946), 1984, Aug-17, Volume: 109, Issue:33

    Topics: Angiography; Anticoagulants; Arterial Occlusive Diseases; Clinical Trials as Topic; Double-Blind Method; Humans; Leg; Placebos; Tablets; Thiophenes; Ticlopidine; Time Factors

1984
Evaluation of the antithrombotic efficacy of ticlopidine in man.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Clinical Trials as Topic; Extracorporeal Circulation; Female; Fibrinolytic Agents; Humans; Leukocyte Count; Male; Premedication; Renal Dialysis; Thiophenes; Thrombocytopenia; Thrombosis; Ticlopidine

1984
Therapeutic effect of ticlopidine for ischemic leg ulcers.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Arterial Occlusive Diseases; Clinical Trials as Topic; Female; Humans; Ischemia; Leg; Leg Ulcer; Male; Thiophenes; Ticlopidine

1984
Ticlopidine and coronary surgery.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Humans; Postoperative Complications; Thiophenes; Ticlopidine

1984
Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anemia, Sickle Cell; Anticoagulants; Clinical Trials as Topic; Double-Blind Method; Humans; Thiophenes; Ticlopidine

1984
The influence of ticlopidine on the natural course of retinal vein occlusion.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Adenosine Diphosphate; Adult; Aged; Anticoagulants; Clinical Trials as Topic; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Platelet Aggregation; Retinal Diseases; Retinal Vein; Risk; Thiophenes; Ticlopidine; Visual Acuity

1984
Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study).
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Anticoagulants; Brain Ischemia; Clinical Trials as Topic; Diabetic Angiopathies; Diabetic Neuropathies; Diabetic Retinopathy; Electrocardiography; Fluorescein Angiography; Follow-Up Studies; Humans; Middle Aged; Patient Compliance; Platelet Aggregation; Thiophenes; Ticlopidine

1984
Ticlopidine: quo vadis? Subarachnoid hemorrhage.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Clinical Trials as Topic; Double-Blind Method; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine

1984
The North American ticlopidine aspirin stroke study: structure, stratification variables, and patient characteristics.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Random Allocation; Thiophenes; Ticlopidine

1984
The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Humans; Ischemic Attack, Transient; Thiophenes; Ticlopidine

1984
Canadian American ticlopidine study (cats) in thromboembolic stroke.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Clinical Trials as Topic; Follow-Up Studies; Humans; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; Patient Compliance; Thiophenes; Ticlopidine

1984
Overview: clinical experiences with ticlopidine.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anemia, Sickle Cell; Anticoagulants; Arterial Occlusive Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypass; Extracorporeal Circulation; Humans; Renal Dialysis; Retinal Diseases; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine

1984
A double-blind trial of ticlopidine in sickle cell disease.
    Thrombosis and haemostasis, 1984, Jul-29, Volume: 51, Issue:3

    Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Blood Coagulation Factors; Blood Platelets; Cell Survival; Clinical Trials as Topic; Double-Blind Method; Female; Heterozygote; Homozygote; Humans; Male; Placebos; Thalassemia; Thiophenes; Ticlopidine

1984
Registry of prospective clinical trials--fifth report.
    Thrombosis and haemostasis, 1982, Dec-27, Volume: 48, Issue:3

    Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Blind Method; Heart Valve Prosthesis; Heparin; Humans; Intermittent Claudication; Myocardial Infarction; Prospective Studies; Registries; Thiophenes; Thromboembolism; Thrombophlebitis; Thrombosis; Ticlopidine

1982
Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo.
    Angiology, 1982, Volume: 33, Issue:6

    Topics: Arterial Occlusive Diseases; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Elbow; Female; Foot; Humans; Ischemia; Knee; Male; Middle Aged; Pain; Placebos; Platelet Aggregation; Skin Ulcer; Thiophenes; Thromboangiitis Obliterans; Ticlopidine

1982
Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.
    Journal of clinical pathology, 1982, Volume: 35, Issue:7

    Topics: Adult; Aged; Arteriosclerosis; Clinical Trials as Topic; Double-Blind Method; Humans; Intermittent Claudication; Male; Middle Aged; Platelet Aggregation; Random Allocation; Thiophenes; Ticlopidine

1982
The effect of Ticlopidine upon platelet function, haemorrhage and post-operative thrombosis in patients undergoing suprapubic prostatectomy.
    The Journal of international medical research, 1981, Volume: 9, Issue:3

    Topics: Bleeding Time; Hemorrhage; Humans; Male; Platelet Function Tests; Postoperative Complications; Prostatectomy; Pyridines; Random Allocation; Thiophenes; Thrombophlebitis; Ticlopidine

1981
Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis.
    Atherosclerosis, 1980, Volume: 36, Issue:4

    Topics: Adenosine Diphosphate; Aged; Arachidonic Acids; Arteriosclerosis; Blood Coagulation; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Thiophenes; Ticlopidine

1980
[Ticlopidine in heart surgery with cardiopulmonary by-pass (author's transl)].
    La Nouvelle presse medicale, 1980, Nov-15, Volume: 9, Issue:43

    Topics: Adolescent; Adult; Aged; Blood Coagulation; Cardiac Surgical Procedures; Extracorporeal Circulation; Humans; Middle Aged; Platelet Aggregation; Postoperative Complications; Pyridines; Thiophenes; Thrombocytopenia; Thrombosis; Ticlopidine

1980
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Circulation, 2005, Jun-28, Volume: 111, Issue:25

    Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Male; Membrane Proteins; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2005
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
    European heart journal, 2006, Volume: 27, Issue:10

    Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2006
Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
    Postgraduate medical journal, 2006, Volume: 82, Issue:968

    Topics: Clopidogrel; Coronary Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine

2006
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
    American heart journal, 2006, Volume: 152, Issue:4

    Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Syndrome; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine; Treatment Outcome

2006
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.
    British journal of clinical pharmacology, 2007, Volume: 63, Issue:4

    Topics: Adolescent; Adult; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2007
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
    American heart journal, 2007, Volume: 153, Issue:1

    Topics: Adult; Area Under Curve; Blood Platelets; Clopidogrel; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine

2007
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Clinical pharmacology and therapeutics, 2007, Volume: 81, Issue:5

    Topics: Adult; Area Under Curve; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2007
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
    Journal of cardiovascular pharmacology, 2007, Volume: 49, Issue:3

    Topics: Adenosine Diphosphate; Adolescent; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine

2007
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:5

    Topics: Adenosine Diphosphate; Adult; Area Under Curve; Blood Platelets; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2007
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
    European heart journal, 2008, Volume: 29, Issue:1

    Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome

2008
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
    Circulation, 2007, Dec-18, Volume: 116, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cross-Over Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome

2007
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:1

    Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flow Cytometry; Humans; Light; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reproducibility of Results; Thiophenes; Ticlopidine; Time Factors

2008
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:2

    Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values; Reproducibility of Results; Thiophenes; Ticlopidine

2008
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Adolescent; Adult; Aged; Area Under Curve; Biological Availability; Clopidogrel; Cross-Over Studies; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine

2008
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
    Lancet (London, England), 2008, Apr-19, Volume: 371, Issue:9621

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2008
[The TRITON-TIMI 38 trial].
    Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine

2008
Approaching an age of reason with antiplatelet therapy.
    Lancet (London, England), 2008, Apr-19, Volume: 371, Issue:9621

    Topics: Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Thrombosis; Ticlopidine

2008
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
    Journal of the American College of Cardiology, 2008, May-27, Volume: 51, Issue:21

    Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine

2008
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Secondary Prevention; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
    Platelets, 2008, Volume: 19, Issue:4

    Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2008
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
    European heart journal, 2008, Volume: 29, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2008
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
    Circulation, 2008, Oct-14, Volume: 118, Issue:16

    Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome

2008
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Current medical research and opinion, 2008, Volume: 24, Issue:8

    Topics: Adult; Chromatography, Liquid; Clopidogrel; Cross-Over Studies; Drug Interactions; Histamine H2 Antagonists; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ranitidine; Tandem Mass Spectrometry; Thiophenes; Ticlopidine

2008
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:4

    Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cell Communication; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Monocytes; P-Selectin; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2008
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Journal of pharmacokinetics and pharmacodynamics, 2008, Volume: 35, Issue:6

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2008
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
    Pharmacotherapy, 2008, Volume: 28, Issue:12

    Topics: Adolescent; Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Chromatography, Liquid; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Epistaxis; Heptanoic Acids; Humans; Liver; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Tandem Mass Spectrometry; Thiophenes; Ticlopidine; United Kingdom; Young Adult

2008
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
    Journal of the American College of Cardiology, 2008, Dec-09, Volume: 52, Issue:24

    Topics: Adult; Aged; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Pyridines; Thiophenes; Ticlopidine; Treatment Failure; Treatment Outcome

2008
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
    American heart journal, 2009, Volume: 157, Issue:3

    Topics: Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Optical Rotation; Phosphorylation; Piperazines; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
    Critical pathways in cardiology, 2009, Volume: 8, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome

2009
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
    European heart journal, 2009, Volume: 30, Issue:14

    Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genetic Variation; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    European heart journal, 2009, Volume: 30, Issue:14

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
    Circulation, 2009, Jun-02, Volume: 119, Issue:21

    Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatine Kinase, MB Form; Death, Sudden, Cardiac; Double-Blind Method; Humans; Incidence; Kaplan-Meier Estimate; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Thiophenes; Ticlopidine; Time Factors; Troponin T

2009
The FDA prasugrel review: adjudication of myocardial infarction controversy.
    Cardiology, 2009, Volume: 114, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration

2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
    Journal of the American College of Cardiology, 2009, Aug-18, Volume: 54, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Stroke; Thiophenes; Ticlopidine

2009
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio
    American heart journal, 2009, Volume: 158, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Paris; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2010
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
    Postgraduate medicine, 2010, Volume: 122, Issue:1

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine

2010
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
    Clinical therapeutics, 2010, Volume: 32, Issue:2

    Topics: Administration, Oral; Adult; Asian People; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Singapore; Thiophenes; Ticlopidine; White People; Young Adult

2010
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:8

    Topics: Aged; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Genetic Variation; Genotype; Humans; Middle Aged; Myocardial Infarction; Pharmacogenetics; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Thiophenes; Ticlopidine; Treatment Outcome

2010
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Administration, Oral; Aged; Angina, Unstable; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Global Health; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Survival Rate; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2010
Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial.
    Current medical research and opinion, 2010, Volume: 26, Issue:9

    Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Algorithms; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine; Young Adult

2010
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.
    Journal of the American College of Cardiology, 2010, Sep-21, Volume: 56, Issue:13

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2010
Antagonism of P2Y₁₂ reduces physiological thromboxane levels.
    Platelets, 2010, Volume: 21, Issue:8

    Topics: Adenosine Diphosphate; Adolescent; Adult; Animals; Blood Platelets; Clopidogrel; Female; Humans; Male; Mice; Mice, Knockout; Middle Aged; Pilot Projects; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thromboxanes; Ticlopidine; Young Adult

2010
Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world.
    International journal of cardiology, 2012, Mar-22, Volume: 155, Issue:3

    Topics: Acute Coronary Syndrome; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome

2012
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy.
    BMC medicine, 2011, Jan-12, Volume: 9

    Topics: Aspirin; Clopidogrel; Demography; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine

2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
    European heart journal, 2011, Volume: 32, Issue:7

    Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult

2011
Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Female; Genotype; Greece; Humans; Least-Squares Analysis; Male; Middle Aged; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymerase Chain Reaction; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Single-Blind Method; Stents; Thiophenes; Ticlopidine; Treatment Outcome

2011
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
    Circulation, 2011, Jun-14, Volume: 123, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombolytic Therapy; Ticlopidine

2011
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
    British journal of clinical pharmacology, 2012, Volume: 73, Issue:1

    Topics: Adult; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Pedigree; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult

2012
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:2

    Topics: Adenosine Diphosphate; Aged; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activating Factor; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2011
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
    American heart journal, 2011, Volume: 162, Issue:3

    Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2011
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.
    American heart journal, 2011, Volume: 162, Issue:4

    Topics: Aged; Chronic Disease; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Thiophenes; Ticlopidine; Treatment Outcome

2011
Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:12

    Topics: Aged; Blood Platelets; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Renal Dialysis; Single-Blind Method; Thiophenes; Ticlopidine

2011
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Thrombosis research, 2012, Volume: 129, Issue:5

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult

2012
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
    Platelets, 2013, Volume: 24, Issue:1

    Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome

2013
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin
    JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:3

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Italy; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2012
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
    Lancet (London, England), 2012, May-05, Volume: 379, Issue:9827

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Carrier Screening; Genetic Testing; Genotype; Humans; Loss of Heterozygosity; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2012
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity
    Journal of the American College of Cardiology, 2012, Jun-12, Volume: 59, Issue:24

    Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2012
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
    Journal of the American College of Cardiology, 2012, Jul-31, Volume: 60, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause of Death; Chest Tubes; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Retrospective Studies; Risk Adjustment; Thiophenes; Ticlopidine

2012
Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study.
    International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5

    Topics: Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Electrodes, Implanted; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome

2013
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
    Journal of the American College of Cardiology, 2012, Jun-19, Volume: 59, Issue:25

    Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2012
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Journal of the American College of Cardiology, 2012, Jul-17, Volume: 60, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2012
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.
    Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:4

    Topics: Adult; Aged; Asian People; Clopidogrel; Cohort Studies; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Preoperative Care; Singapore; Thiophenes; Ticlopidine

2012
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
    The New England journal of medicine, 2012, Oct-04, Volume: 367, Issue:14

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine

2012
Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction.
    Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:5

    Topics: Aged; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2012
Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:5

    Topics: Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rome; Thiophenes; Ticlopidine; Treatment Outcome

2012
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
    International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1

    Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Tetrazoles; Thiophenes; Ticlopidine

2013
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    JAMA, 2012, Nov-07, Volume: 308, Issue:17

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Retreatment; Stents; Thiophenes; Ticlopidine

2012
A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
    Archives of cardiovascular diseases, 2012, Volume: 105, Issue:11

    Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Drugs, Generic; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Stents; Therapeutic Equivalency; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2012
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
    Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2013
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Substitution; Female; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Pharmacogenetics; Phenotype; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Treatment Outcome

2013
Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity.
    American heart journal, 2013, Volume: 165, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome

2013
Pharmacodynamic comparisons for single loading doses of prasugrel (30 mg) and clopidogrel (600 mg) in healthy Korean volunteers.
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:5

    Topics: Adult; Analysis of Variance; Asian People; Clopidogrel; Cross-Over Studies; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Republic of Korea; Thiophenes; Ticlopidine; Time Factors; Young Adult

2013
Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.
    Trials, 2013, Feb-28, Volume: 14

    Topics: Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Republic of Korea; Research Design; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2013
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
    Diabetes care, 2013, Volume: 36, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticagrelor; Ticlopidine

2013
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Journal of the American College of Cardiology, 2013, Aug-06, Volume: 62, Issue:6

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine

2013
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
    Journal of the American College of Cardiology, 2013, Aug-13, Volume: 62, Issue:7

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Reference Values; Severity of Illness Index; Single-Blind Method; Survival Rate; Thiophenes; Ticlopidine; Treatment Outcome

2013
Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Thrombosis research, 2013, Volume: 132, Issue:1

    Topics: Abciximab; Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Administration Routes; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2013
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Circulation, 2013, Aug-20, Volume: 128, Issue:8

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome

2013
A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.
    International journal of cardiology, 2013, Oct-09, Volume: 168, Issue:4

    Topics: Aged; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Thiophenes; Ticlopidine; Treatment Outcome

2013
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
    Lancet (London, England), 2013, Aug-17, Volume: 382, Issue:9892

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2013
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    International journal of cardiology, 2013, Oct-15, Volume: 168, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine

2013
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:6

    Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Activation; Polymorphism, Genetic; Prasugrel Hydrochloride; Prospective Studies; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2013
Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.
    Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Circadian Rhythm; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome

2013
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET):
    Circulation. Cardiovascular interventions, 2013, Oct-01, Volume: 6, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Practice Guidelines as Topic; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
    European heart journal, 2014, Volume: 35, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin

2014
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
    Journal of the American College of Cardiology, 2014, Jan-28, Volume: 63, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2014
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:2

    Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2014
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    The American journal of cardiology, 2014, Jan-01, Volume: 113, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Survival Rate; Sweden; Thiophenes; Ticlopidine; Treatment Outcome

2014
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Risk Factors; Stroke; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2013
Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
    Platelets, 2014, Volume: 25, Issue:7

    Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Thiophenes; Ticlopidine; Treatment Outcome

2014
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:4

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Receptors, Purinergic P2Y12; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2014
A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:2

    Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome

2013
Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial).
    The American journal of cardiology, 2014, May-01, Volume: 113, Issue:9

    Topics: Antithrombins; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome

2014
Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.
    Clinical cardiology, 2014, Volume: 37, Issue:5

    Topics: Anticoagulants; Clopidogrel; Drug Therapy, Combination; Female; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome

2014
Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience.
    Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3

    Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
    Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3

    Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Sex Factors; Stents; Thiophenes; Thrombosis; Ticlopidine

2014
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2014
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:7

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors

2014
Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
    European heart journal, 2014, Sep-07, Volume: 35, Issue:34

    Topics: Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Therapy, Combination; Early Termination of Clinical Trials; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome

2014
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
    European heart journal. Acute cardiovascular care, 2014, Volume: 3, Issue:4

    Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome

2014
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Plate
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:6

    Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome

2014
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
    American heart journal, 2014, Volume: 168, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Smoking; Survival Rate; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United Kingdom; United States

2014
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Thrombosis and haemostasis, 2014, Sep-02, Volume: 112, Issue:3

    Topics: Aged; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome

2014
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:9

    Topics: Adult; Aged; Anti-Ulcer Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2014
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
    Current medical research and opinion, 2014, Volume: 30, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine

2014
The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.
    Clinical science (London, England : 1979), 2015, Volume: 128, Issue:2

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Regression Analysis; Thiophenes; Ticlopidine

2015
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:12

    Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Elective Surgical Procedures; Female; Follow-Up Studies; Gene Frequency; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine

2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Time Factors

2014
Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thieno
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:1 Pt B

    Topics: Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Vessels; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphoproteins; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; Vascular Patency

2015
Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
    Transfusion, 2015, Volume: 55, Issue:6

    Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Flow Cytometry; Half-Life; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guideline Adherence; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult

2015
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention
    American heart journal, 2015, Volume: 169, Issue:4

    Topics: Administration, Oral; Aged; Atrial Fibrillation; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Rivaroxaban; Thiophenes; Ticlopidine; Treatment Outcome; Vitamin K

2015
[Twelve or thirty months of dual antiplatelet Therapy after drug-eluting stents. Results of the DAPT trial].
    Kardiologiia, 2015, Volume: 55, Issue:1

    Topics: Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2015
Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention.
    Bangladesh Medical Research Council bulletin, 2013, Volume: 39, Issue:3

    Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome

2013
ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016, Dec-10, Volume: 12, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Thiophenes; Ticlopidine

2016
Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y
    British journal of clinical pharmacology, 2020, Volume: 86, Issue:9

    Topics: Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Humans; Male; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Thiophenes; Ticlopidine

2020

Other Studies

405 other study(ies) available for ticlopidine and thiophenes

ArticleYear
[Use of a new platelet aggregation inhibitor, ticlopidine, in hemodialysis].
    Archivio "E. Maragliano" di patologia e clinica, 1979, Volume: 35, Issue:2

    Topics: Adult; Aged; Blood Coagulation Disorders; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation; Pyridines; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine

1979
Effects of ticlopidine on platelet prostaglandin metabolism. Possible consequences for prostacyclin production.
    Prostaglandins and medicine, 1979, Volume: 2, Issue:6

    Topics: Adenosine Diphosphate; Anticoagulants; Arachidonic Acids; Blood Platelets; Epoprostenol; Humans; In Vitro Techniques; Platelet Aggregation; Prostaglandin Endoperoxides; Prostaglandins; Prostaglandins E; Pyridines; Thiophenes; Ticlopidine

1979
[Changes of blood coagulability and effects of the platelet aggregation inhibitor (ticlopidine) in experimental subarachnoid hemorrhage in dogs].
    Neurologia medico-chirurgica, 1985, Volume: 25, Issue:10

    Topics: Animals; Anticoagulants; Basilar Artery; Blood Coagulation; Dogs; Fibrinogen; Platelet Aggregation; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine

1985
Antithrombotic agents in necrobiosis lipoidica.
    Acta dermato-venereologica, 1986, Volume: 66, Issue:1

    Topics: Adolescent; Adult; Diabetes Complications; Female; Fibrinolytic Agents; Humans; Necrobiosis Lipoidica; Thiophenes; Ticlopidine

1986
Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs.
    Thrombosis research, 1985, Oct-15, Volume: 40, Issue:2

    Topics: Aged; Arteriosclerosis Obliterans; beta-Thromboglobulin; Blood Platelets; Double-Blind Method; Drug Synergism; Epoprostenol; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Factor 4; Thiophenes; Thromboxane B2; Ticlopidine

1985
[Should ticlopidine be forbidden for hemodialysis patients waiting for renal transplantation?].
    Presse medicale (Paris, France : 1983), 1985, Dec-14, Volume: 14, Issue:43

    Topics: Anticoagulants; Humans; Kidney Transplantation; Renal Dialysis; Thiophenes; Ticlopidine

1985
[Does the use of ticlopidine in hemodialyzed patients contraindicate renal transplantation?].
    Presse medicale (Paris, France : 1983), 1986, Feb-22, Volume: 15, Issue:8

    Topics: Anticoagulants; Humans; Kidney Transplantation; Renal Dialysis; Risk; Thiophenes; Ticlopidine

1986
Effect of the antiplatelet agents ticlopidine and dipyridamole on experimental immune complex glomerulonephritis in rats.
    Nephron, 1986, Volume: 43, Issue:1

    Topics: Animals; Antibodies; Antigen-Antibody Complex; Cattle; Creatinine; Dipyridamole; Fluorescent Antibody Technique; Glomerulonephritis; Immune Complex Diseases; Injections, Subcutaneous; Kidney Function Tests; Male; Platelet Aggregation; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Serum Albumin, Bovine; Thiophenes; Ticlopidine; Time Factors; Urea

1986
Mechanism of interaction of ticlopidine and its analogues with the energy-conserving mechanism in mitochondria.
    Biochemical pharmacology, 1986, Jun-01, Volume: 35, Issue:11

    Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Animals; Anticoagulants; Biological Transport; Energy Metabolism; Kinetics; Male; Mitochondria, Liver; Mitochondrial ADP, ATP Translocases; Oxygen Consumption; Platelet Aggregation; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Thiophenes; Ticlopidine

1986
[Abnormalities of blood coagulation and effect of anticoagulant therapy in postoperative patients with lung cancer].
    Nihon Geka Gakkai zasshi, 1986, Volume: 87, Issue:6

    Topics: Adult; Aged; Anticoagulants; beta-Thromboglobulin; Blood Coagulation Disorders; Female; Humans; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Thiophenes; Ticlopidine; Warfarin

1986
Immunomodulatory activity of anti-atherogenic drugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune complexes.
    Immunopharmacology, 1985, Volume: 9, Issue:2

    Topics: Anaphylaxis; Animals; Antibody Formation; Antigen-Antibody Complex; Arteriosclerosis; Clofibrate; Clofibric Acid; Cyclic AMP; Cyclic GMP; Female; Hypersensitivity, Delayed; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Niacin; Thiophenes; Ticlopidine

1985
Platelet-dependent granulocyte activation in vitro: effect of ticlopidine.
    International journal of tissue reactions, 1985, Volume: 7, Issue:5

    Topics: Adenosine Diphosphate; Blood Platelets; Cytochalasin B; Glucuronidase; Humans; In Vitro Techniques; Neutrophils; Platelet Aggregation; Superoxides; Thiophenes; Ticlopidine

1985
Spin label study of the effect of ticlopidine on platelets.
    Japanese journal of pharmacology, 1985, Volume: 39, Issue:1

    Topics: Animals; Anticoagulants; Blood Platelets; Blood Proteins; Chemical Phenomena; Chemistry, Physical; Cholesterol; Electron Spin Resonance Spectroscopy; In Vitro Techniques; Male; Membrane Fluidity; Phospholipids; Rats; Rats, Inbred Strains; Sodium Dodecyl Sulfate; Spin Labels; Thiophenes; Ticlopidine

1985
Long-term low dose ticlopidine treatment in rheumatoid arthritis: effects on serum sulphydryl levels, technetium index, erythrocyte sedimentation rate, and clinical disease activity.
    European journal of clinical pharmacology, 1985, Volume: 29, Issue:2

    Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Female; Humans; Male; Middle Aged; Radionuclide Imaging; Sodium Pertechnetate Tc 99m; Sulfhydryl Compounds; Thiophenes; Ticlopidine

1985
Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.
    The Journal of clinical investigation, 1985, Volume: 75, Issue:2

    Topics: Adenosine Triphosphate; Adult; Animals; Bleeding Time; Blood Platelet Disorders; Blood Platelets; Clot Retraction; Female; Fibrinogen; Glycoproteins; Humans; In Vitro Techniques; Male; Membrane Proteins; Platelet Aggregation; Platelet Membrane Glycoproteins; Rats; Thiophenes; Ticlopidine; von Willebrand Factor

1985
[Use of ticlopidine in chronic hemodialyzed patients. Counter-indication in future renal transplant receivers].
    Presse medicale (Paris, France : 1983), 1985, Apr-20, Volume: 14, Issue:16

    Topics: Adult; Anticoagulants; Humans; Kidney Transplantation; Male; Renal Dialysis; Thiophenes; Ticlopidine

1985
Effects of ticlopidine on platelet function and on coronary insufficiency in patients with angina pectoris.
    Advances in prostaglandin, thromboxane, and leukotriene research, 1985, Volume: 13

    Topics: Adult; Aged; Angina Pectoris; Blood Platelets; Coronary Disease; Humans; Male; Middle Aged; Nitroglycerin; Platelet Function Tests; Thiophenes; Ticlopidine; Time Factors

1985
Metabolic side effects of the platelet-inhibitory drug ticlopidine.
    Advances in prostaglandin, thromboxane, and leukotriene research, 1985, Volume: 13

    Topics: Adult; Aged; Angina Pectoris; Blood Platelets; Cholesterol; Humans; Male; Middle Aged; Thiophenes; Ticlopidine; Time Factors; Triglycerides

1985
Microcirculatory changes during skin allograft rejection and prolongation of survival time by antiplatelet agents.
    International journal of tissue reactions, 1986, Volume: 8, Issue:2

    Topics: Acrylates; Animals; Arterioles; Azathioprine; Blood Platelets; Capillaries; Graft Occlusion, Vascular; Graft Rejection; Graft Survival; Male; Methacrylates; Mice; Mice, Inbred BALB C; Microscopy, Electron; Skin; Skin Transplantation; Thiophenes; Thromboembolism; Thromboxane-A Synthase; Ticlopidine; Transplantation, Homologous; Transplantation, Isogeneic; Venules

1986
Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis.
    Thrombosis research, 1986, May-01, Volume: 42, Issue:3

    Topics: Animals; Aspirin; Blood Coagulation Disorders; Cattle; Collagen; Dogs; Hemorrhage; Hemostatic Techniques; Hemostatics; Heparin; Spleen; Thiophenes; Thrombocytopenia; Ticlopidine; Warfarin

1986
Antithrombotic effects of sodium salt of 17(R)-methyl-20-isopropylidenecarbacyclin in the arteriole of the hamster cheek pouch.
    Arzneimittel-Forschung, 1986, Volume: 36, Issue:4

    Topics: Adenosine Diphosphate; Animals; Arteries; Cheek; Cricetinae; Dipyridamole; Epoprostenol; Fibrinolytic Agents; Male; Mesocricetus; Regional Blood Flow; Thiophenes; Ticlopidine; Time Factors

1986
Ticlopidine and platelet function.
    Thrombosis and haemostasis, 1986, Jun-30, Volume: 55, Issue:3

    Topics: Adenosine Diphosphate; Drug Synergism; Epoprostenol; Humans; Platelet Aggregation; Thiophenes; Ticlopidine

1986
[Cholestatic fatty liver of probably iatrogenic origin].
    Recenti progressi in medicina, 1986, Volume: 77, Issue:4

    Topics: Anticoagulants; Cholestasis, Intrahepatic; Fatty Liver; Female; Humans; Iatrogenic Disease; Middle Aged; Thiophenes; Ticlopidine

1986
Swelling of mitochondria by the platelet antiaggregating agent ticlopidine.
    Biochemical pharmacology, 1986, Jun-01, Volume: 35, Issue:11

    Topics: Animals; Anticoagulants; Chloramphenicol; Kinetics; Male; Mitochondria, Liver; Mitochondrial Swelling; Oxidative Phosphorylation; Oxygen Consumption; Platelet Aggregation; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine; Uncoupling Agents

1986
[Control of platelet antiaggregation therapy using an electronic aggregometer on whole blood].
    Minerva cardioangiologica, 1986, Volume: 34, Issue:4

    Topics: Aged; Arterial Occlusive Diseases; Equipment and Supplies; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Ticlopidine

1986
[Influencing the effectiveness of repeatedly used dialyzers by the administration of ticlopidine (Ticlid)].
    Vnitrni lekarstvi, 1986, Volume: 32, Issue:4

    Topics: Adult; Blood Platelets; Creatinine; Female; Heparin; Humans; Male; Renal Dialysis; Thiophenes; Ticlopidine; Urea

1986
Ticlopidine versus aspirin and dipyridamole: influence on platelet deposition and three-month patency of polytetrafluoroethylene grafts.
    Journal of vascular surgery, 1986, Volume: 4, Issue:2

    Topics: Animals; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Female; Femoral Artery; Graft Occlusion, Vascular; Indium; Male; Platelet Aggregation; Polytetrafluoroethylene; Radioisotopes; Thiophenes; Ticlopidine

1986
Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine.
    Thrombosis and haemostasis, 1986, Jun-30, Volume: 55, Issue:3

    Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Line; Female; Humans; In Vitro Techniques; Male; Middle Aged; Neuroblastoma; Perfusion; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine

1986
[Antagonism of collagen-induced ECG changes in rats by a thromboxane synthetase inhibitor, CV-4151].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1986, Volume: 87, Issue:4

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Collagen; Coronary Disease; Electrocardiography; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Humans; Pyridines; Rats; Rats, Inbred Strains; Thiophenes; Thromboxane B2; Ticlopidine

1986
[Prevention and medical treatment of polyregional vascular lesions].
    Cardiologia (Rome, Italy), 1985, Volume: 30, Issue:11

    Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Risk; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine

1985
[Ticlid].
    Soins; la revue de reference infirmiere, 1985, Issue:454

    Topics: Anticoagulants; Blood Platelet Disorders; Humans; Thiophenes; Ticlopidine

1985
Anaemia and agranulocytosis associated with ticlopidine therapy.
    Acta haematologica, 1985, Volume: 73, Issue:4

    Topics: Agranulocytosis; Anemia; Blood Protein Electrophoresis; Bone Marrow Examination; Cells, Cultured; Female; Humans; Lymphocytes; Middle Aged; Thiophenes; Ticlopidine

1985
[Activity of ticlopidine and lysine acetylsalicylate in experimental atheromatosis. Effects on the production of PGI2].
    Archivos de farmacologia y toxicologia, 1985, Volume: 11, Issue:2

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteriosclerosis; Aspirin; Diet, Atherogenic; Epoprostenol; Lysine; Male; Platelet Aggregation; Rabbits; Thiophenes; Ticlopidine

1985
Membrane expansion as a mechanism explaining the antisickling action of ticlopidine observed in vitro.
    American journal of hematology, 1985, Volume: 18, Issue:2

    Topics: Anemia, Sickle Cell; Antisickling Agents; Densitometry; Erythrocyte Membrane; Humans; Kinetics; Osmotic Fragility; Oxygen Consumption; Sickle Cell Trait; Thiophenes; Ticlopidine

1985
Antiplatelet aggregators inhibit development of stress ulcers in Sprague-Dawley rats.
    European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 1985, Volume: 17, Issue:1

    Topics: Animals; Anticoagulants; Aspirin; Capillaries; Dipyridamole; Gastric Mucosa; Male; Platelet Aggregation; Pyridines; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Physiological; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine

1985
Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis.
    Thrombosis research, 1985, Jan-15, Volume: 37, Issue:2

    Topics: Animals; Aspirin; Blood Platelets; Fibrinolytic Agents; Male; Rats; Rats, Inbred Strains; Thiophenes; Thrombophlebitis; Ticlopidine

1985
Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival.
    Thrombosis research, 1985, Jan-01, Volume: 37, Issue:1

    Topics: Animals; Anticoagulants; Blood Platelets; Cell Survival; In Vitro Techniques; Male; Neuraminidase; Platelet Adhesiveness; Platelet Aggregation; Rabbits; Rats; Rats, Inbred Strains; Thiophenes; Thrombosis; Ticlopidine

1985
Intracoronary platelet activation in ischemic heart disease: effects of ticlopidine.
    American heart journal, 1985, Volume: 109, Issue:4

    Topics: Adult; Aged; Anticoagulants; Aorta; Blood Platelets; Coronary Disease; Coronary Vessels; Female; Humans; Male; Middle Aged; Platelet Factor 4; Thiophenes; Ticlopidine

1985
[Antithrombogenic therapy based on the study of the changes in platelet aggregability and blood coagulability in the early period after prosthetic valve replacement].
    [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai, 1985, Volume: 33, Issue:1

    Topics: Adult; Anticoagulants; Blood Coagulation; Dipyridamole; Female; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation; Postoperative Complications; Thiophenes; Thrombosis; Ticlopidine; Warfarin

1985
A clinically relevant model of heart failure: effects of ticlopidine.
    Cardiovascular research, 1985, Volume: 19, Issue:4

    Topics: Animals; Blood Pressure; Coronary Circulation; Disease Models, Animal; Embolism; Female; Heart Failure; Heart Rate; Male; Platelet Aggregation; Swine; Thiophenes; Ticlopidine

1985
Effect of ticlopidine on neutrophil chemotaxis in rats.
    Haemostasis, 1985, Volume: 15, Issue:2

    Topics: Adenosine Diphosphate; Administration, Oral; Animals; Cell Membrane; Chemotaxis, Leukocyte; Depression, Chemical; Male; Neutrophils; Platelet Aggregation; Rats; Thiophenes; Ticlopidine; Zymosan

1985
[Agranulocytosis caused by ticlopidine].
    Recenti progressi in medicina, 1985, Volume: 76, Issue:5

    Topics: Aged; Agranulocytosis; Anticoagulants; Bone Marrow; Female; Humans; Male; Middle Aged; Thiophenes; Ticlopidine

1985
[Bone marrow culture in patients treated with Ticlopidine].
    Nouvelle revue francaise d'hematologie, 1985, Volume: 27, Issue:1

    Topics: Adult; Aged; Agranulocytosis; Alprostadil; Anticoagulants; Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Female; Granulocytes; Humans; Male; Middle Aged; Prostaglandins E; Thiophenes; Ticlopidine

1985
Ticlopidine as a hemorrhagic risk factor in coronary surgery.
    Drug intelligence & clinical pharmacy, 1985, Volume: 19, Issue:9

    Topics: Adult; Coronary Disease; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Count; Postoperative Complications; Retrospective Studies; Risk; Thiophenes; Ticlopidine

1985
[Prevention of thrombosis of a blood vessel prosthesis using the anti-aggregation drug ticlid].
    Kardiologiia, 1985, Volume: 25, Issue:8

    Topics: Blood Vessel Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine

1985
Platelet sequestration during hypothermia in dogs treated with sulphinpyrazone and ticlopidine--reversibility accelerated after intra-abdominal rewarming.
    Thrombosis and haemostasis, 1985, Dec-17, Volume: 54, Issue:4

    Topics: Animals; Blood Platelets; Dogs; Hemodynamics; Hot Temperature; Hypothermia; Liver; Platelet Aggregation; Sulfinpyrazone; Thiophenes; Thrombocytopenia; Ticlopidine

1985
[Status and trends in the field of inhibitors of thrombocyte function].
    Folia haematologica (Leipzig, Germany : 1928), 1984, Volume: 111, Issue:4

    Topics: Animals; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation; Thiophenes; Thrombosis; Thromboxane-A Synthase; Ticlopidine

1984
In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Adenosine Diphosphate; Anticoagulants; Blood Platelets; Fibrinogen; Humans; In Vitro Techniques; Platelet Aggregation; Platelet Membrane Glycoproteins; Receptors, Cell Surface; Thiophenes; Ticlopidine

1984
Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
    Haemostasis, 1983, Volume: 13, Issue:1

    Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Heparin; Lasers; Male; Mesenteric Arteries; Mesenteric Vascular Occlusion; Molsidomine; Oxazoles; Platelet Aggregation; Propionates; Pyrazoles; Pyrazolones; Rats; Rats, Inbred Strains; Sydnones; Thiophenes; Thrombosis; Ticlopidine

1983
Ticlopidine can cause chronic diarrhoea.
    Lancet (London, England), 1984, Feb-18, Volume: 1, Issue:8373

    Topics: Aged; Anticoagulants; Chronic Disease; Diarrhea; Humans; Male; Thiophenes; Ticlopidine

1984
[Effects of ticlopidine on the plasma levels of beta-thromboglobulin and thromboxane B2 in types 1 and 2 diabetics].
    Minerva medica, 1984, Jul-31, Volume: 75, Issue:30-31

    Topics: Beta-Globulins; beta-Thromboglobulin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Thiophenes; Thromboxane B2; Thromboxanes; Ticlopidine

1984
[Results in peripheral arterial revascularization with the use of various antiaggregating substances].
    Revista clinica espanola, 1984, May-31, Volume: 173, Issue:4

    Topics: Adult; Aged; Anticoagulants; Blood Vessel Prosthesis; Dicumarol; Graft Occlusion, Vascular; Humans; Middle Aged; Thiophenes; Ticlopidine

1984
Beta-thromboglobulin and platelet factor 4 in polycythemia patients treated by ticlopidine.
    Acta haematologica, 1984, Volume: 72, Issue:2

    Topics: Anticoagulants; Beta-Globulins; beta-Thromboglobulin; Erythrocyte Count; Humans; Platelet Count; Platelet Factor 4; Polycythemia; Thiophenes; Ticlopidine

1984
[Side effects of ticlopidine; clinical observation and immunological study].
    Nederlands tijdschrift voor geneeskunde, 1982, Jun-05, Volume: 126, Issue:23

    Topics: Aged; Agranulocytosis; Antibodies; Drug Eruptions; Female; Humans; Male; Middle Aged; Purpura, Thrombocytopenic; Thiophenes; Ticlopidine

1982
The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs.
    Annals of the Royal College of Surgeons of England, 1984, Volume: 66, Issue:4

    Topics: Arteries; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination; Humans; Microscopy, Electron; Platelet Adhesiveness; Platelet Aggregation; Polyethylene Terephthalates; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine

1984
[Evaluation of platelet aggregation in patients treated with ticlopidine].
    La Clinica terapeutica, 1984, Nov-15, Volume: 111, Issue:3

    Topics: Adult; Aged; Anticoagulants; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Thromboembolism; Ticlopidine

1984
[Quantification (by nomograms) of physiopathological parameters in an experimental model of passive anaphylaxis caused by immune complexes].
    Revista espanola de fisiologia, 1984, Volume: 40, Issue:3

    Topics: Anaphylaxis; Animals; Cyproheptadine; Immune Complex Diseases; Mathematics; Mice; Mice, Inbred Strains; Shock, Septic; Thiophenes; Ticlopidine

1984
Interaction of ticlopidine with the erythrocyte membrane.
    Biochemical pharmacology, 1982, Dec-15, Volume: 31, Issue:24

    Topics: Blood Proteins; Electron Spin Resonance Spectroscopy; Electrophoresis, Polyacrylamide Gel; Erythrocyte Membrane; Erythrocytes; Humans; In Vitro Techniques; Osmosis; Spin Labels; Thiophenes; Ticlopidine

1982
[Cholestatic hepatitis. Presumptive role of ticlopidine].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1983, Nov-17, Volume: 59, Issue:42

    Topics: Aged; Chemical and Drug Induced Liver Injury; Cholestasis; Female; Humans; Thiophenes; Ticlopidine

1983
Comparative effects of ticlopidine and analogues on in vitro myeloid colony (CFU-GM) growth.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Animals; Anticoagulants; Bone Marrow; Chloramphenicol; Chlorpromazine; Colony-Stimulating Factors; DNA; Granulocytes; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Macrophages; Mice; Mice, Inbred C57BL; Thiophenes; Ticlopidine

1984
New horizons in cardiology.
    International journal of cardiology, 1984, Volume: 6, Issue:5

    Topics: Adult; Angina, Unstable; Anticoagulants; Coronary Disease; Coronary Vessels; Electrocardiography; Female; Humans; Male; Methacrylates; Middle Aged; Myocardial Infarction; Perfusion; Stroke Volume; Thiophenes; Thromboxane A2; Thromboxane B2; Ticlopidine; Tomography, Emission-Computed; Urokinase-Type Plasminogen Activator

1984
The effect of ticlopidine on human endothelial cells in culture.
    Thrombosis research, 1984, Feb-01, Volume: 33, Issue:3

    Topics: Anticoagulants; Cell Adhesion; Cell Differentiation; Culture Techniques; Endothelium; Fibronectins; Fluorescent Antibody Technique; Humans; Thiophenes; Ticlopidine; Umbilical Veins

1984
The effect of 5-(2-chlorobenzyl)-5,6,7,7a-tetrahydro 4H-thieno (3.2-C)-pyridine-2-one hydrochloride (PCR 3787), a metabolite of ticlopidine, on the aggregation of human platelets in vitro and on the aggregation inhibiting action of PGI2 and PGD2.
    Prostaglandins, leukotrienes, and medicine, 1984, Volume: 16, Issue:3

    Topics: Collagen; Epoprostenol; Humans; Platelet Aggregation; Prostaglandin D2; Prostaglandins D; Thiophenes; Ticlopidine

1984
Effects of ticlopidine and dexamethasone on fibronectin and factor VIII-related antigen synthesis by cultured endothelial cells.
    Thrombosis research. Supplement, 1983, Volume: 4

    Topics: Antigens; Cells, Cultured; Dexamethasone; Endothelium; Factor VIII; Fibrinolytic Agents; Fibronectins; Humans; In Vitro Techniques; Muscle, Smooth, Vascular; Thiophenes; Ticlopidine; von Willebrand Factor

1983
[Changes in the unmodified vessels after aortocoronary bypass surgery].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1983, Volume: 139, Issue:6

    Topics: Angina Pectoris; Anticoagulants; Arterial Occlusive Diseases; Coronary Artery Bypass; Coronary Disease; Humans; Male; Middle Aged; Prospective Studies; Thiophenes; Ticlopidine

1983
[Changes in arterial blood gases after hemodialysis and the influence of platelet antiaggregation].
    Medicina clinica, 1984, May-26, Volume: 82, Issue:20

    Topics: Adult; Blood Gas Analysis; Carbon Dioxide; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oxygen; Partial Pressure; Renal Dialysis; Thiophenes; Ticlopidine

1984
The effect of oral ticlopidine on arachidonic acid products in human platelets.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Administration, Oral; Anticoagulants; Arachidonic Acid; Arachidonic Acids; Blood Platelets; Collagen; Dose-Response Relationship, Drug; Humans; Malondialdehyde; Platelet Aggregation; Thiophenes; Thromboxane B2; Ticlopidine

1984
[The effect of ticlopidine and lysine acetylsalicylate on fibrinolytic activity of the arterial wall in experimental atherosclerosis].
    Archivos de farmacologia y toxicologia, 1984, Volume: 10, Issue:3

    Topics: Animals; Arteriosclerosis; Aspirin; Fibrinolysis; Lysine; Male; Muscle, Smooth, Vascular; Rabbits; Thiophenes; Ticlopidine

1984
Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
    Artery, 1980, Volume: 8, Issue:5

    Topics: Adenosine Diphosphate; Animals; Antibodies; Arthus Reaction; Aspirin; Dipyridamole; Forssman Antigen; Guinea Pigs; Humans; Nervous System Diseases; Platelet Count; Pyridines; Sulfides; Sulfinpyrazone; Thiophenes; Thrombocytopenia; Ticlopidine

1980
Effects of various antiplatelet drugs and defibrinating agent on experimental glomerulonephritis in rats.
    The Journal of laboratory and clinical medicine, 1982, Volume: 99, Issue:3

    Topics: Animals; Anticoagulants; Aspirin; Batroxobin; Blood Platelets; Dipyridamole; Glomerulonephritis; Immune Complex Diseases; Kidney; Nephritis; Proteinuria; Pyridines; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine

1982
Effects of long-term ticlopidine treatment on platelet function and its tolerability in cerebrovascular disease.
    The Journal of international medical research, 1984, Volume: 12, Issue:5

    Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Blood Platelets; Cerebrovascular Disorders; Female; Fibrinogen; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Thiophenes; Ticlopidine; Time Factors

1984
[Thrombocytopenia due to antibodies induced by ticlopidine].
    Nouvelle revue francaise d'hematologie, 1984, Volume: 26, Issue:5

    Topics: Aged; Antibody Formation; Anticoagulants; Arteriosclerosis; Blood Platelets; Humans; Platelet Count; Thiophenes; Thrombocytopenia; Ticlopidine

1984
Effects of ticlopidine, a new platelet antiaggregating agent, and its analogues on mitochondrial metabolism. Oxidative phosphorylation, protein synthesis and DNA polymerase activity.
    Biochemical pharmacology, 1984, Dec-01, Volume: 33, Issue:23

    Topics: Animals; Anticoagulants; DNA-Directed DNA Polymerase; Kinetics; Male; Mitochondria, Liver; Oxidative Phosphorylation; Oxygen Consumption; Platelet Aggregation; Protein Biosynthesis; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Thiophenes; Ticlopidine

1984
[Ticlopidine in the prevention of recurrent cerebral ischemic accidents].
    Medicina clinica, 1984, Oct-20, Volume: 83, Issue:12

    Topics: Anticoagulants; Brain Ischemia; Humans; Recurrence; Thiophenes; Ticlopidine

1984
[Ticlopidine as something more than a platelet antiaggregant].
    Archivos de farmacologia y toxicologia, 1984, Volume: 10, Issue:2

    Topics: Animals; In Vitro Techniques; Lipids; Platelet Aggregation; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine

1984
[Darier's erythema annulare centrifugum and primary Vaquez polycythemia].
    Annales de dermatologie et de venereologie, 1984, Volume: 111, Issue:8

    Topics: Aged; Erythema; Follow-Up Studies; Humans; Male; Paraneoplastic Syndromes; Phosphorus Radioisotopes; Polycythemia Vera; Thiophenes; Ticlopidine

1984
[Comparative action of different platelet anti-aggregants in the postoperative period].
    Cahiers d'anesthesiologie, 1984, Volume: 32, Issue:2

    Topics: Anticoagulants; Dipyridamole; Humans; Papaverine; Parasympatholytics; Platelet Aggregation; Postoperative Complications; Postoperative Period; Thiophenes; Thrombophlebitis; Ticlopidine

1984
[Thrombus formation and its prevention during extracorporeal circulation--effect of preoperative administration with the antiplatelet drugs].
    [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai, 1984, Volume: 32, Issue:12

    Topics: Adult; Dipyridamole; Extracorporeal Circulation; Humans; Microscopy, Electron, Scanning; Platelet Adhesiveness; Platelet Aggregation; Platelet Count; Preoperative Care; Thiophenes; Thrombosis; Ticlopidine

1984
In vitro study of ticlopidine, as a model of antisickling action of platelet antiaggregant.
    Haematologia, 1984, Volume: 17, Issue:2

    Topics: Anticoagulants; Antisickling Agents; Erythrocyte Membrane; Hemoglobin, Sickle; Humans; In Vitro Techniques; Thiophenes; Ticlopidine

1984
In vivo study of platelet aggregation in rats.
    Journal of pharmacological methods, 1984, Volume: 12, Issue:2

    Topics: Adenosine Diphosphate; Animals; Aspirin; Collagen; Diet; Dose-Response Relationship, Drug; Male; Methods; Platelet Aggregation; Platelet Count; Rats; Rats, Inbred Strains; Thiophenes; Thrombosis; Ticlopidine

1984
[Case of thrombotic thrombocytopenic purpura. Successful treatment with ticlopidine].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1984, Volume: 25, Issue:7

    Topics: Adult; Anticoagulants; Female; Humans; Purpura, Thrombotic Thrombocytopenic; Thiophenes; Ticlopidine

1984
Ex vivo and in vivo evaluation of drugs that inhibit platelet function.
    Annals of the New York Academy of Sciences, 1983, Volume: 416

    Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Blood Platelets; Collagen; Dipyridamole; Imidazoles; Male; Papio; Platelet Aggregation; Sulfinpyrazone; Thiazines; Thiophenes; Ticlopidine

1983
Ticlopidine: quo vadis?
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Animals; Anticoagulants; Humans; Thiophenes; Ticlopidine

1984
Ex vivo effects of ticlopidine on human platelets: inhibition of fibrinogen binding by a mechanism independent of thromboxane formation.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Blood Platelets; Fibrinogen; Humans; Platelet Aggregation; Thiophenes; Thromboxanes; Ticlopidine

1984
Ticlopidine: quo vadis? Adverse reactions in man.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Aspirin; Diarrhea; Humans; Neutropenia; Product Surveillance, Postmarketing; Thiophenes; Ticlopidine

1984
Toxicological studies of ticlopidine in laboratory animals.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Animals; Anticoagulants; Blood; Carcinogens; Dose-Response Relationship, Drug; Female; Mice; Mutagens; Papio; Rabbits; Rats; Reproduction; Thiophenes; Ticlopidine

1984
Beneficial effects of ticlopidine on cardiopulmonary function of sickle cell patients not in crisis.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Heart; Heart Rate; Humans; Lung; Oxygen; Physical Exertion; Thiophenes; Ticlopidine

1984
Ticlopidine as an experimental antithrombotic agent.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Animals; Anticoagulants; Blood Coagulation; Blood Vessels; Carotid Arteries; Fibrinolytic Agents; Platelet Aggregation; Rats; Thiophenes; Thrombophlebitis; Ticlopidine

1984
Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Adenosine Diphosphate; Adult; Aged; Anticoagulants; Female; Humans; In Vitro Techniques; Male; Methods; Middle Aged; Platelet Aggregation; Spectrophotometry; Thiophenes; Ticlopidine

1984
Ticlopidine and adenylate cyclase.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Adenylyl Cyclases; Alprostadil; Animals; Blood Platelets; Enzyme Activation; Male; Prostaglandins E; Rabbits; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine

1984
[Effect of ticlopidine in the prevention of recurrences of cerebral ischemic accidents: comparative study with dipyridamol].
    Medicina clinica, 1984, Jan-21, Volume: 82, Issue:2

    Topics: Brain Ischemia; Dipyridamole; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Humans; Male; Rectum; Recurrence; Thiophenes; Ticlopidine

1984
Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study.
    The Annals of thoracic surgery, 1984, Volume: 37, Issue:5

    Topics: Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Postoperative Complications; Radiography; Random Allocation; Saphenous Vein; Thiophenes; Ticlopidine

1984
Thrombotic etiology of stress ulcers. 1. The effect of anticoagulant and antiplatelet aggregators in the development of stress ulcers in rats.
    The American surgeon, 1983, Volume: 49, Issue:8

    Topics: Animals; Anticoagulants; Aspirin; Dipyridamole; Gastric Acidity Determination; Gastric Mucosa; Heparin; Male; Peptic Ulcer Hemorrhage; Platelet Aggregation; Platelet Count; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Physiological; Thiophenes; Thrombosis; Ticlopidine

1983
On-line diode array UV-visible spectrometry in screening for drugs and drug metabolites by high-performance liquid chromatography.
    Journal of chromatography, 1983, Sep-16, Volume: 267, Issue:2

    Topics: Amiodarone; Animals; Bile; Biotransformation; Chromatography, High Pressure Liquid; Humans; Male; Middle Aged; Pharmaceutical Preparations; Rats; Rats, Inbred Strains; Spectrophotometry; Spectrophotometry, Ultraviolet; Thiophenes; Ticlopidine

1983
Effect of intergranular versus intragranular cornstarch on tablet friability and in vitro dissolution.
    Journal of pharmaceutical sciences, 1983, Volume: 72, Issue:9

    Topics: Hardness; Microscopy, Electron, Scanning; Solubility; Starch; Tablets; Thiophenes; Ticlopidine; Time Factors

1983
Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications.
    Haemostasis, 1983, Volume: 13 Suppl 1

    Topics: Animals; Anticoagulants; Blood Platelets; Hemodynamics; Humans; Kinetics; Thiophenes; Thrombosis; Ticlopidine

1983
Anti-platelet drugs during chronic hemodialysis: an experience with ticlopidine, the 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno-[3,2-c] pyridine.
    Il Farmaco; edizione pratica, 1983, Volume: 38, Issue:12

    Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation; Renal Dialysis; Thiophenes; Ticlopidine

1983
Effects of ticlopidine and aspirin on endotoxin-induced disseminated intravascular coagulation in rats.
    Thrombosis and haemostasis, 1983, Dec-30, Volume: 50, Issue:4

    Topics: Animals; Aspirin; Disseminated Intravascular Coagulation; Rats; Thiophenes; Ticlopidine

1983
[Platelet antiaggregants and bleeding time lengthening: management in the preoperative period].
    Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression, 1983, Volume: 24, Issue:12

    Topics: Adrenal Cortex Hormones; Aspirin; Blood Coagulation; Humans; Platelet Aggregation; Preoperative Care; Thiophenes; Ticlopidine

1983
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
    Arquivos brasileiros de cardiologia, 1983, Volume: 41, Issue:6

    Topics: Anticoagulants; Bleeding Time; Humans; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine

1983
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
    Agents and actions, 1984, Volume: 14, Issue:1

    Topics: Adenosine Diphosphate; Aspirin; Bleeding Time; Blood Platelets; Fibrinolytic Agents; Humans; Thiophenes; Thrombosis; Ticlopidine

1984
A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study.
    Clinical nephrology, 1984, Volume: 21, Issue:3

    Topics: Adult; Creatinine; Diabetic Nephropathies; Double-Blind Method; Drug Evaluation; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Platelet Aggregation; Random Allocation; Thiophenes; Ticlopidine

1984
Platelet survival, atherosclerotic intermittent claudication and ticlopidine.
    Atherosclerosis, 1984, Volume: 50, Issue:2

    Topics: Aged; Arteriosclerosis; Blood Platelets; Cell Survival; Humans; Indium; Intermittent Claudication; Male; Middle Aged; Radioisotopes; Thiophenes; Ticlopidine

1984
Effects of antiplatelet agents on pulmonary metastases.
    Gan, 1984, Volume: 75, Issue:3

    Topics: Adenosine Diphosphate; Animals; Depression, Chemical; Diltiazem; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Platelet Aggregation; Thiophenes; Ticlopidine; Trapidil

1984
[Structural aspects of the kidney in experimental atheromatosis].
    Revista clinica espanola, 1984, Apr-15, Volume: 173, Issue:1

    Topics: Animals; Arteriosclerosis; Blood Platelets; Fibrinolysis; Kidney; Male; Platelet Aggregation; Rabbits; Salicylates; Thiophenes; Ticlopidine; Tranexamic Acid

1984
Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets.
    Thrombosis research, 1984, Jun-15, Volume: 34, Issue:6

    Topics: Adenosine Diphosphate; Animals; Arachidonic Acids; Humans; Platelet Activating Factor; Platelet Aggregation; Rabbits; Thiophenes; Ticlopidine

1984
The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets.
    Thrombosis and haemostasis, 1981, Volume: 46, Issue:3

    Topics: Anticoagulants; Blood Platelets; Cells, Cultured; Depression, Chemical; Factor VIII; Fibrinogen; Humans; In Vitro Techniques; Platelet Aggregation; Pyridines; Thiophenes; Ticlopidine

1981
The effect of ticlopidine on the aggregation of rat blood platelets and on the formation of metabolites from arachidonic acid and 8,11,14-eicosatrienoic acid in rat platelets during aggregation, and in the rat kidney.
    Agents and actions, 1982, Volume: 12, Issue:3

    Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Arachidonic Acids; Biotransformation; Blood Platelets; Collagen; Fatty Acids, Unsaturated; Kidney; Male; Platelet Aggregation; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine

1982
Platelet aggregation measured in rabbit whole blood: in vitro study of 3 aggregating agents and ex vivo inhibition by aspirin and ticlopidine.
    Archives internationales de pharmacodynamie et de therapie, 1982, Volume: 259, Issue:2

    Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Collagen; In Vitro Techniques; Platelet Aggregation; Platelet Count; Rabbits; Thiophenes; Ticlopidine

1982
Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin.
    Agents and actions, 1983, Volume: 13, Issue:1

    Topics: Adult; Aged; Anticoagulants; Aspirin; Epinephrine; Humans; In Vitro Techniques; Middle Aged; Platelet Activating Factor; Platelet Aggregation; Thiophenes; Ticlopidine

1983
[The effects of ticlopidine on platelet aggregation: study on 13 atherosclerotic patients].
    La Clinica terapeutica, 1983, Feb-15, Volume: 104, Issue:3

    Topics: Aged; Anticoagulants; Arteriosclerosis; Female; Humans; Male; Platelet Aggregation; Thiophenes; Ticlopidine

1983
Spinal subarachnoid hematoma after lumbar puncture in a patient receiving antiplatelet therapy.
    Anesthesia and analgesia, 1983, Volume: 62, Issue:8

    Topics: Aged; Anesthesia, Spinal; Anticoagulants; Female; Hematoma; Humans; Postoperative Complications; Spinal Cord Diseases; Spinal Puncture; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine

1983
Effects of ticlopidine and aspirin on endotoxin-induced disseminated intravascular coagulation in rats.
    Thrombosis and haemostasis, 1983, Jun-28, Volume: 49, Issue:3

    Topics: Animals; Aspirin; Disease Models, Animal; Disseminated Intravascular Coagulation; Endotoxins; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Kidney Glomerulus; Partial Thromboplastin Time; Platelet Count; Prothrombin Time; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine

1983
[Platelet aggregation inhibitors].
    Revue de l'infirmiere, 1981, Volume: 31, Issue:19

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Dipyridamole; Humans; Platelet Aggregation; Pyridines; Thiophenes; Thrombosis; Ticlopidine

1981
Comparison between the antiaggregating effect of ticlopidine in whole blood, platelet-rich plasma and washed platelets of the rat.
    Thrombosis research, 1982, Apr-01, Volume: 26, Issue:1

    Topics: Adenosine Diphosphate; Animals; Dinoprostone; Epoprostenol; In Vitro Techniques; Male; Plasma; Platelet Aggregation; Prostaglandins E; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine

1982
[Hematological toxicity of ticlopidine? (author's transl)].
    Nouvelle revue francaise d'hematologie, 1982, Volume: 24, Issue:1

    Topics: Aged; Agranulocytosis; Female; Humans; Male; Middle Aged; Pancytopenia; Platelet Aggregation; Thiophenes; Ticlopidine

1982
Multiple human serum binding of two thienopyridinic derivatives, ticlopidine and PCR 2362, and their distribution between HSA, alpha1-acid glycoprotein and lipoproteins.
    Biochemical pharmacology, 1982, Mar-01, Volume: 31, Issue:5

    Topics: Humans; Lipoproteins; Orosomucoid; Platelet Aggregation; Protein Binding; Serum Albumin; Thiophenes; Ticlopidine

1982
[Physicochemical study of ticlopidine absorption kinetics on human platelet membrane (author's transl)].
    Journal des maladies vasculaires, 1982, Volume: 7, Issue:2

    Topics: Adsorption; Blood Platelets; Cell Membrane; Chemical Phenomena; Chemistry, Physical; Humans; Kinetics; Membrane Fluidity; Thiophenes; Ticlopidine

1982
[Platelet release proteins in plasma in peripheral arterial obliterative disease during ticlopidine administration].
    Deutsche medizinische Wochenschrift (1946), 1982, Sep-17, Volume: 107, Issue:37

    Topics: Adult; Arterial Occlusive Diseases; Blood Coagulation Factors; Double-Blind Method; Female; Humans; Male; Platelet Factor 4; Thiophenes; Ticlopidine

1982
A possible method to control prolongations of bleeding time under antiplatelet therapy with ticlopidine.
    Thrombosis and haemostasis, 1982, Aug-24, Volume: 48, Issue:1

    Topics: Adenosine Diphosphate; Administration, Oral; Adult; Bleeding Time; Female; Humans; Hydrocortisone; Injections, Intravenous; Male; Platelet Aggregation; Prednisolone; Thiophenes; Ticlopidine; Vasoconstrictor Agents

1982
Platelet survival in patients treated with ticlopidine following reconstructive arterial surgery.
    Thrombosis research, 1982, Aug-01, Volume: 27, Issue:3

    Topics: Aged; Aorta; Blood Platelets; Blood Vessel Prosthesis; Cell Survival; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Postoperative Complications; Thiophenes; Ticlopidine

1982
Antiaggregant effect of ticlopidine in atherosclerotic patients.
    Il Farmaco; edizione pratica, 1982, Volume: 37, Issue:10

    Topics: Aged; Arteriosclerosis; Female; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Ticlopidine

1982
A comparison of ticlopidine and heparin on hemodialysis in dogs.
    The Journal of laboratory and clinical medicine, 1982, Volume: 100, Issue:6

    Topics: Animals; Anorexia; Diarrhea; Dogs; Heparin; Renal Dialysis; Thiophenes; Ticlopidine; Uremia

1982
A new in vivo model of arterial thrombosis: the effect of administration of ticlopidine and verapamil in dogs.
    Thrombosis research, 1982, Dec-01, Volume: 28, Issue:5

    Topics: Administration, Oral; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Femoral Artery; Fibrinolytic Agents; Injections, Intravenous; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine; Verapamil

1982
Modulation of the inhibitory action of prostaglandin E1 on platelet aggregation in rats: a study with ticlopidine, aspirin, dipyridamole and sulfinpyrazone.
    Biochemical pharmacology, 1982, Mar-15, Volume: 31, Issue:6

    Topics: Adenosine Diphosphate; Alprostadil; Animals; Aspirin; Dipyridamole; Male; Phosphorylation; Platelet Aggregation; Prostaglandins E; Rats; Rats, Inbred Strains; Sulfinpyrazone; Thiophenes; Ticlopidine

1982
Effects of long term administration of ticlopidine on platelet function and hemostatic variables.
    Thrombosis research, 1980, Oct-01, Volume: 20, Issue:1

    Topics: Adult; Afibrinogenemia; Aged; Antithrombin III; Bleeding Time; Blood Platelets; Blood Sedimentation; Female; Fibrinogen; Hemostasis; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Thiophenes; Ticlopidine; Time Factors

1980
Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study.
    Thrombosis research, 1980, Oct-15, Volume: 20, Issue:2

    Topics: Adult; Aged; Blood Urea Nitrogen; Chlorides; Creatinine; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Kidney Failure, Chronic; Male; Middle Aged; Phosphoric Acids; Platelet Count; Pyridines; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine

1980
[Effects of ticlopidine on blood circulation and thrombin-induced platelet aggregation in experimental diabetic rats- and it's efficacy for remedy of diabetic retinopathy (author's transl)].
    Nippon Ganka Gakkai zasshi, 1981, Volume: 85, Issue:3

    Topics: Animals; Blood Circulation; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Platelet Aggregation; Pyridines; Rats; Thiophenes; Thrombin; Ticlopidine

1981
Effect of ticlopidine on arachidonic acid metabolism in platelet phospholipids in vitro.
    Biochemical pharmacology, 1981, Jun-15, Volume: 30, Issue:12

    Topics: Arachidonic Acids; Blood Platelets; Humans; In Vitro Techniques; Phosphatidylcholines; Phosphatidylinositols; Phospholipids; Pyridines; Thiophenes; Ticlopidine

1981
Metabolism of ticlopidine in rats: identification and quantitative determination of some its metabolites in plasma, urine and bile.
    European journal of drug metabolism and pharmacokinetics, 1981, Volume: 6, Issue:2

    Topics: Animals; Bile; Biotransformation; Chemical Phenomena; Chemistry; Chromatography, Gas; Chromatography, Thin Layer; Male; Pyridines; Rats; Thiophenes; Ticlopidine

1981
Compression properties of granulations made with binders containing different moisture contents.
    Journal of pharmaceutical sciences, 1981, Volume: 70, Issue:10

    Topics: Drug Compounding; Excipients; Hardness; Humidity; Powders; Pressure; Pyridines; Tablets; Thiophenes; Ticlopidine

1981
Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
    Cancer research, 1981, Volume: 41, Issue:11 Pt 1

    Topics: Animals; Cell Line; Female; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplastic Cells, Circulating; Platelet Aggregation; Pyridines; Rats; Thiophenes; Ticlopidine

1981
Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys.
    Artificial organs, 1980, Volume: 4, Issue:1

    Topics: Adult; Arteriovenous Shunt, Surgical; Blood Coagulation; Female; Fibrinolytic Agents; Humans; Kidneys, Artificial; Middle Aged; Platelet Aggregation; Pyridines; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine

1980
Antithrombotic effects of ticlopidine, acetylsalicyclic acid and dipyridamole in vascular shunt model in rats.
    Thrombosis research, 1980, Mar-01, Volume: 17, Issue:5

    Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Blood Coagulation Tests; Dipyridamole; Fibrinogen; Fibrinolytic Agents; Hematocrit; Male; Platelet Aggregation; Platelet Count; Pyridines; Rats; Serum Globulins; Thiophenes; Ticlopidine

1980
Pharmacological studies on ticlopidine, a new platelet aggregation inhibitor. Part I: Cardiovascular effects.
    Arzneimittel-Forschung, 1980, Volume: 30, Issue:3

    Topics: Animals; Cerebrovascular Circulation; Coronary Circulation; Dogs; Ear; Female; Heart Rate; Hemodynamics; In Vitro Techniques; Male; Muscle Tonus; Myocardium; Oxygen Consumption; Papaverine; Platelet Aggregation; Pyridines; Rabbits; Rats; Regional Blood Flow; Respiration; Thiophenes; Ticlopidine

1980
[Migraine or transient ischemic attacks in a patient with essential thrombocythaemia. Treatment with ticlopidine (author's transl)].
    Annales de medecine interne, 1980, Volume: 131, Issue:2

    Topics: Blood Platelets; Humans; Ischemic Attack, Transient; Male; Middle Aged; Migraine Disorders; Platelet Aggregation; Pyridines; Thiophenes; Thrombocytosis; Ticlopidine

1980
Effect of ticlopidine on human platelet responsiveness ex vivo: comparison with aspirin.
    Thrombosis research, 1980, Jun-15, Volume: 18, Issue:6

    Topics: Adenosine Diphosphate; Adult; Aspirin; Collagen; Dose-Response Relationship, Drug; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Serotonin; Thiophenes; Ticlopidine

1980
Effect of ticlopidine treatment on liver metabolizing enzymes in man.
    British journal of clinical pharmacology, 1980, Volume: 10, Issue:3

    Topics: Adult; Antipyrine; Enzyme Induction; Half-Life; Humans; Liver; Male; Microsomes, Liver; Pyridines; Thiophenes; Ticlopidine

1980
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    British journal of pharmacology, 2000, Volume: 129, Issue:7

    Topics: Adenosine Diphosphate; Administration, Oral; Animals; Arteriovenous Shunt, Surgical; Binding, Competitive; Bleeding Time; Blood Platelets; Clopidogrel; Collagen; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Thionucleotides; Thiophenes; Thrombin; Thrombosis; Ticlopidine; Time Factors; Tritium

2000
Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases.
    Drug metabolism and disposition: the biological fate of chemicals, 2004, Volume: 32, Issue:1

    Topics: Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; DNA, Complementary; Horseradish Peroxidase; Humans; In Vitro Techniques; Insecta; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microsomes, Liver; Monoamine Oxidase; Oxidation-Reduction; Peroxidases; Platelet Aggregation Inhibitors; Pyridinium Compounds; Thiophenes; Ticlopidine

2004
Prasugrel, clopidogrel, and combining Swedish apples with American oranges.
    European heart journal, 2006, Volume: 27, Issue:15

    Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2006
Highly selective copper-catalyzed ring expansion of vinyl thiiranes: application to synthesis of biotin and the heterocyclic core of plavix.
    Journal of the American Chemical Society, 2007, Mar-14, Volume: 129, Issue:10

    Topics: Biotin; Catalysis; Clopidogrel; Copper; Heterocyclic Compounds; Sulfides; Thiophenes; Ticlopidine; Vinyl Compounds

2007
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:7

    Topics: Adenosine Diphosphate; Alprostadil; Animals; Blood Platelets; Clopidogrel; Cyclic AMP; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine

2007
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
    The American journal of cardiology, 2007, Jul-15, Volume: 100, Issue:2

    Topics: Clopidogrel; Humans; Nephelometry and Turbidimetry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors

2007
Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
    American heart journal, 2007, Volume: 154, Issue:4

    Topics: Adenosine; Antifibrinolytic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2007
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:12

    Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Genotype; Humans; Male; Middle Aged; Mixed Function Oxygenases; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values; Research Design; Retrospective Studies; Thiophenes; Ticlopidine

2007
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2007
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    European journal of pharmacology, 2008, Jan-28, Volume: 579, Issue:1-3

    Topics: Administration, Oral; Adult; Animals; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; In Vitro Techniques; Macaca fascicularis; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Thiophenes; Thrombosis; Ticlopidine

2008
[Prasugrel, a new thienopyridine].
    Hamostaseologie, 2007, Volume: 27, Issue:5

    Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine

2007
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
    Platelets, 2008, Volume: 19, Issue:2

    Topics: Adenosine Monophosphate; Adult; Annexin A5; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytoplasmic Granules; Humans; In Vitro Techniques; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2008
[Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007].
    Revue medicale suisse, 2008, Feb-13, Volume: 4, Issue:144

    Topics: Clopidogrel; Congresses as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2008
Prasugrel versus clopidogrel.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine

2008
Prasugrel versus clopidogrel.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine

2008
Prasugrel versus clopidogrel.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2008
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
    Cardiology, 2008, Volume: 111, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hematemesis; Hematuria; Hemorrhage; Humans; Intracranial Hemorrhages; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2008
Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?).
    The American journal of cardiology, 2008, May-01, Volume: 101, Issue:9

    Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Treatment Outcome

2008
A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.
    The American journal of cardiology, 2008, May-01, Volume: 101, Issue:9

    Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Humans; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome

2008
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
    Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:7

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2008
For better or for worse: the future of antiplatelet therapy.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine

2008
Multiple electrode aggregometry and P2Y(12) antagonists.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:6

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Electrodes; Equipment Design; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2008
Antiplatelet therapy in acute coronary syndromes.
    Current cardiology reports, 2008, Volume: 10, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2008
[Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15].
    Kardiologia polska, 2008, Volume: 66, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome

2008
Intensive antiplatelet therapy for reduction of ischaemic events.
    Lancet (London, England), 2008, Aug-16, Volume: 372, Issue:9638

    Topics: Clopidogrel; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Time Factors

2008
[Prasugrel versus Clopidogrel in patients with acute coronary syndromes. Results of the TRITON-TIMI 38 trial].
    Kardiologiia, 2008, Volume: 48, Issue:8

    Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2008
Modulation of clopidogrel pharmacodynamic response.
    Pharmacotherapy, 2008, Volume: 28, Issue:12

    Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Clopidogrel; Drug Interactions; Heptanoic Acids; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Thiophenes; Ticlopidine

2008
Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.
    Drug metabolism and disposition: the biological fate of chemicals, 2009, Volume: 37, Issue:3

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Humans; Lactones; Microsomes, Liver; Oxidoreductases, N-Demethylating; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.
    Journal of the American College of Cardiology, 2008, Dec-09, Volume: 52, Issue:24

    Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticlopidine; Treatment Failure

2008
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
    Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2009
Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
    Drug metabolism and pharmacokinetics, 2008, Volume: 23, Issue:6

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Oxidoreductases, N-Demethylating; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine

2008
Another view on prasugrel.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome

2009
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Thiophenes; Thrombosis; Ticlopidine

2009
Facts and controversies of aspirin and clopidogrel therapy.
    American heart journal, 2009, Volume: 157, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine

2009
Ischaemia versus bleeding: the art of clinical decision-making.
    Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2009
Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
    Xenobiotica; the fate of foreign compounds in biological systems, 2009, Volume: 39, Issue:3

    Topics: Animals; Area Under Curve; Clopidogrel; Cytochrome P-450 Enzyme System; Dogs; Hydrolysis; Male; Molecular Structure; Oxidation-Reduction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine

2009
Novel antiplatelet strategies in acute coronary syndromes.
    Cleveland Clinic journal of medicine, 2009, Volume: 76 Suppl 1

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2009
Prasugrel STEMI subgroup analysis.
    Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678

    Topics: Clopidogrel; Data Interpretation, Statistical; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome

2009
Prasugrel STEMI subgroup analysis.
    Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678

    Topics: Clopidogrel; Data Interpretation, Statistical; Drug Administration Schedule; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome

2009
Prasugrel STEMI subgroup analysis.
    Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678

    Topics: Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine

2009
Can we override clopidogrel resistance?
    Circulation, 2009, Jun-02, Volume: 119, Issue:21

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Restenosis; Drug Resistance; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Prodrugs; Radiography; Stents; Thiophenes; Ticlopidine

2009
Future of oral antiplatelet therapy: four challenged hypotheses.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:6

    Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2009
Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel.
    Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:5

    Topics: Clopidogrel; Commerce; Drug Costs; Humans; Insurance, Pharmaceutical Services; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine

2009
Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.
    Arzneimittel-Forschung, 2009, Volume: 59, Issue:5

    Topics: Animals; Biotransformation; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
[Pharmazie in unserer Zeit 4/2009].
    Pharmazie in unserer Zeit, 2009, Volume: 38, Issue:4

    Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine

2009
Test before you stop.
    Archives of surgery (Chicago, Ill. : 1960), 2009, Volume: 144, Issue:8

    Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2009
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
    Thrombosis research, 2009, Volume: 124, Issue:5

    Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; Hemostasis; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine; Transfection

2009
Cardiovascular disease gets personal.
    Nature, 2009, Aug-20, Volume: 460, Issue:7258

    Topics: Anticoagulants; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Female; Genetic Predisposition to Disease; Genetic Testing; Genetic Variation; Genome-Wide Association Study; Genomics; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin

2009
A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
    Drug metabolism and disposition: the biological fate of chemicals, 2009, Volume: 37, Issue:11

    Topics: Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Humans; Microsomes, Liver; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine

2009
Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2009
Risk of combining PPIs with thienopyridines: fact or fiction?
    Lancet (London, England), 2009, Sep-19, Volume: 374, Issue:9694

    Topics: Biotransformation; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Thiophenes; Ticlopidine

2009
[New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome].
    MMW Fortschritte der Medizin, 2009, Sep-03, Volume: 151, Issue:36

    Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2009
[Prasugrel or clopidogrel in patients with coronary intervention].
    Der Internist, 2009, Volume: 50, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine

2009
Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
    Xenobiotica; the fate of foreign compounds in biological systems, 2009, Volume: 39, Issue:11

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Kinetics; Microsomes, Liver; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Stent thrombosis: who's guilty?
    European heart journal, 2009, Volume: 30, Issue:22

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Vessel Prosthesis; Cardiology; Clinical Competence; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Graft Occlusion, Vascular; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine

2009
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire international, 2009, Volume: 18, Issue:103

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2009
[Changing times for clopidogrel].
    Medizinische Monatsschrift fur Pharmazeuten, 2009, Volume: 32, Issue:10

    Topics: Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine

2009
Clopidogrel versus prasugrel: times are changing, but not for everyone.
    Pharmacotherapy, 2009, Volume: 29, Issue:12

    Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
    Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:12

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2009
Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines.
    European heart journal, 2009, Volume: 30, Issue:23

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2009
The TRITON versus PLATO trials: differences beyond platelet inhibition.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2010
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
    Circulation, 2010, Jan-05, Volume: 121, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States

2010
Ticagrelor in ACS: redefining a new standard of care?
    Lancet (London, England), 2010, Jan-23, Volume: 375, Issue:9711

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2010
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome

2010
Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
    Circulation, 2010, Mar-16, Volume: 121, Issue:10

    Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine

2010
Trial watch. DAPT study.
    Harvard heart letter : from Harvard Medical School, 2010, Volume: 20, Issue:5

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2010
Delays of event adjudication in the TRITON trial.
    Cardiology, 2010, Volume: 115, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary Restenosis; Data Collection; Disease-Free Survival; Hemorrhage; Myocardial Infarction; Observer Variation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Stents; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration

2010
Prasugrel, Māori, and personalised medicine in New Zealand.
    The New Zealand medical journal, 2010, Mar-05, Volume: 123, Issue:1310

    Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Markers; Genetic Testing; Humans; Native Hawaiian or Other Pacific Islander; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Precision Medicine; Stents; Thiophenes; Thrombosis; Ticlopidine; Vascular Diseases

2010
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
    Journal of cardiovascular pharmacology, 2010, Volume: 56, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2010
[Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course].
    MMW Fortschritte der Medizin, 2010, Apr-01, Volume: 152, Issue:13

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiology; Clinical Trials as Topic; Clopidogrel; Emergencies; Fibrinolysis; Forecasting; Humans; Length of Stay; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors

2010
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
    Kardiologiia, 2010, Volume: 50, Issue:6

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2010
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by O
    Circulation, 2010, Aug-24, Volume: 122, Issue:8

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome

2010
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Lancet (London, England), 2010, Oct-16, Volume: 376, Issue:9749

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2010
Response to antiplatelet treatment: from genes to outcome.
    Lancet (London, England), 2010, Oct-16, Volume: 376, Issue:9749

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine

2010
Effects of thienopyridines and thienopyrimidinones on L-type calcium current in isolated cardiomyocytes.
    Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 382, Issue:5-6

    Topics: Action Potentials; Animals; Atrial Appendage; Calcium Channels, L-Type; Cells, Cultured; Clopidogrel; Guinea Pigs; Heart Ventricles; Humans; In Vitro Techniques; Myocytes, Cardiac; Patch-Clamp Techniques; Platelet Aggregation Inhibitors; Pyrimidines; Thienopyridines; Thiophenes; Ticlopidine

2010
Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel.
    Platelets, 2011, Volume: 22, Issue:1

    Topics: Aged; Angioedema; Clopidogrel; Drug Hypersensitivity; Exanthema; Fever; Humans; Male; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tachycardia; Thiophenes; Thrombosis; Ticlopidine

2011
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Hospital practice (1995), 2010, Volume: 38, Issue:4

    Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2010
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.
    Journal of thrombosis and thrombolysis, 2011, Volume: 31, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents; Clopidogrel; Docetaxel; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Taxoids; Thiophenes; Thrombosis; Ticlopidine

2011
Prasugrel and cancer.
    Archives of internal medicine, 2010, Nov-22, Volume: 170, Issue:21

    Topics: Clinical Trials as Topic; Clopidogrel; Humans; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2010
[Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].
    Herz, 2010, Volume: 35, Issue:8

    Topics: Aftercare; Anticoagulants; Cardiovascular Agents; Clopidogrel; Combined Modality Therapy; Contraindications; Electrocardiography; Emergency Medical Services; Emergency Service, Hospital; Europe; Evidence-Based Medicine; Humans; Life Style; Myocardial Infarction; Myocardial Reperfusion; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Time Factors

2010
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Guidelines as Topic; Hemorrhage; Humans; Myocardial Infarction; Patient Care Planning; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Standard of Care; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome

2010
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.
    American heart journal, 2010, Volume: 160, Issue:6 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Safety; Secondary Prevention; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin

2010
Resistance to anti-platelet agents.
    Thrombosis research, 2011, Volume: 127 Suppl 3

    Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2011
[Do genetic factors reduce the effects of clopidogrel?].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15

    Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Humans; Isoenzymes; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2011
[Multiple arterial thrombosis and resistance to conventional antiaggregation].
    Revista espanola de cardiologia, 2011, Volume: 64, Issue:9

    Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; Female; Femoral Artery; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine

2011
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2011, Volume: 100, Issue:10

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Electrodes; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome

2011
Prasugrel as a safe alternative for clopidogrel-associated arthritis.
    The Journal of invasive cardiology, 2011, Volume: 23, Issue:6

    Topics: Arthritis; Clopidogrel; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2011
Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events.
    BMJ (Clinical research ed.), 2011, Jun-17, Volume: 342

    Topics: Administration, Oral; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2011
[Specificities of diabetes in acute coronary syndromes].
    Revue medicale suisse, 2011, Jun-01, Volume: 7, Issue:297

    Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Humans; Hypoglycemic Agents; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Stents; Thiophenes; Ticlopidine; Treatment Outcome

2011
Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel.
    The Journal of invasive cardiology, 2011, Volume: 23, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure; Treatment Outcome

2011
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Interactions; Electrocardiography; Female; Heart Arrest; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stents; Thiophenes; Ticlopidine; Time Factors

2011
Direct vasoactive properties of thienopyridine-derived nitrosothiols.
    Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:5

    Topics: Animals; Aorta, Thoracic; Clopidogrel; Glutathione; Guanylate Cyclase; Hydrogen-Ion Concentration; In Vitro Techniques; Luminescent Measurements; Male; Mass Spectrometry; Molecular Structure; Nitro Compounds; Oxadiazoles; Ozone; Piperazines; Prasugrel Hydrochloride; Quinoxalines; Rabbits; S-Nitrosothiols; Sodium Nitrite; Spectrophotometry, Ultraviolet; Thienopyridines; Thiophenes; Ticlopidine; Vasodilation; Vasodilator Agents

2011
Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 339, Issue:2

    Topics: Aryl Hydrocarbon Hydroxylases; Baculoviridae; Biosensing Techniques; Biotransformation; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Assays; Humans; Microsomes; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet-Rich Plasma; Prasugrel Hydrochloride; Thienopyridines; Thiophenes; Ticlopidine

2011
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
    Hospital practice (1995), 2011, Volume: 39, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Diagnostic Techniques and Procedures; Drug Therapy, Combination; Dyspnea; Emergency Service, Hospital; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2011
Use of prasugrel in a patient with clopidogrel hypersensitivity.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2011
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
    The Medical letter on drugs and therapeutics, 2011, Sep-05, Volume: 53, Issue:1372

    Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States

2011
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim.
    Heart, lung & circulation, 2012, Volume: 21, Issue:3

    Topics: Acute Disease; Aspirin; Chest Pain; Clopidogrel; Eptifibatide; Female; Humans; Middle Aged; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Risk Factors; Stents; Thiophenes; Thrombosis; Ticlopidine; Ultrasonography, Interventional

2012
Allergic reaction to prasugrel and cross-reactivity with clopidogrel.
    International journal of cardiology, 2012, Jun-14, Volume: 157, Issue:3

    Topics: Aged; Clopidogrel; Cross Reactions; Female; Humans; Hypersensitivity; Piperazines; Prasugrel Hydrochloride; Pruritus; Thiophenes; Ticlopidine

2012
Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:6

    Topics: Aged; Aged, 80 and over; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2011
Cost-effectiveness of prasugrel in a US managed care population.
    Journal of medical economics, 2012, Volume: 15, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cost Control; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Interviews as Topic; Male; Managed Care Programs; Middle Aged; Models, Economic; Outcome Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States

2012
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.
    European heart journal, 2012, Volume: 33, Issue:10

    Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine

2012
Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity.
    International journal of cardiology, 2012, Feb-09, Volume: 154, Issue:3

    Topics: Blood Platelet Disorders; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2012
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
    Cardiology journal, 2011, Volume: 18, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Metals; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2011
Successful use of prasugrel, an alternative antiplatelet agent, in a patient with clopidogrel allergy.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011, Volume: 107, Issue:6

    Topics: Clopidogrel; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2011
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
    Thrombosis research, 2012, Volume: 130, Issue:1

    Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Clopidogrel; Muscle Contraction; Myocytes, Smooth Muscle; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Thiophenes; Ticagrelor; Ticlopidine

2012
Toward a therapeutic window for antiplatelet therapy in the elderly.
    European heart journal, 2012, Volume: 33, Issue:10

    Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2012
"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Feb-01, Volume: 79, Issue:2

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Decision Making; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine

2012
Desensitization to prasugrel: cardiology's increased need for allergy consultation.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 108, Issue:2

    Topics: Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Desensitization, Immunologic; Drug Dosage Calculations; Drug Hypersensitivity; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Stents; Thiophenes; Ticlopidine

2012
Management of a hypersensitivity reaction to thienopyridines: prasugrel-induced fever and hepatitis resolved after switching to clopidogrel.
    Revista espanola de cardiologia (English ed.), 2012, Volume: 65, Issue:8

    Topics: Adult; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Female; Fever; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2012
Prasugrel as a safe alternative for clopidogrel-induced polyarthralgias.
    Pharmacotherapy, 2012, Volume: 32, Issue:2

    Topics: Arthralgia; Clopidogrel; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2012
[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
    Kardiologia polska, 2012, Volume: 70, Issue:2

    Topics: Abciximab; Adenosine; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine

2012
[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].
    Kardiologia polska, 2012, Volume: 70, Issue:2

    Topics: Adenosine; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Theoretical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine

2012
Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
    Journal of medicinal chemistry, 2012, Apr-12, Volume: 55, Issue:7

    Topics: Administration, Oral; Animals; Biological Availability; Clopidogrel; Drug Resistance; Female; In Vitro Techniques; Male; Mice; Microsomes, Liver; Phenylacetates; Platelet Aggregation Inhibitors; Prodrugs; Rats; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Ticlopidine

2012
A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.
    Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Probability; Risk Assessment; Thiophenes; Ticlopidine

2012
Cost is not a barrier to implementing clopidogrel pharmacogenetics.
    Pharmacotherapy, 2012, Volume: 32, Issue:4

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine

2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
    Pharmacotherapy, 2012, Volume: 32, Issue:4

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Drugs, Generic; Genotype; Hemorrhage; Humans; Models, Economic; Models, Statistical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine

2012
Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; New Zealand; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome

2013
Using models to predict the future: what to do when the data run out?
    Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2012
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Economics, Pharmaceutical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States

2012
Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
    Biopharmaceutics & drug disposition, 2012, Volume: 33, Issue:5

    Topics: Clopidogrel; Drug Interactions; Humans; In Vitro Techniques; Microsomes, Liver; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine

2012
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
    Platelets, 2012, Volume: 23, Issue:5

    Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel: a commentary.
    Pharmacotherapy, 2012, Volume: 32, Issue:6

    Topics: Aryl Hydrocarbon Hydroxylases; Humans; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombolytic Therapy; Ticlopidine

2012
CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
    Connecticut medicine, 2012, Volume: 76, Issue:5

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Treatment Outcome

2012
P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients?
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:2

    Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2012
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    The American journal of medicine, 2012, Volume: 125, Issue:9

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin

2012
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
    Heart advisor, 2010, Volume: 13, Issue:5

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2010
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
    Der Anaesthesist, 2012, Volume: 61, Issue:8

    Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive System Surgical Procedures; Drug Interactions; Hemorrhage; Humans; Male; Middle Aged; Pain, Postoperative; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine

2012
High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.
    Platelets, 2013, Volume: 24, Issue:6

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Heterozygote; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine

2013
Failure of high-dose clopidogrel in recurrent stent thrombosis.
    Singapore medical journal, 2012, Volume: 53, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure

2012
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
    PharmacoEconomics, 2012, Nov-01, Volume: 30, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Diagnosis-Related Groups; Drugs, Generic; Female; Genetic Testing; Hospital Costs; Hospitalization; Humans; Male; Middle Aged; Monte Carlo Method; Native Hawaiian or Other Pacific Islander; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Thiophenes; Ticlopidine

2012
Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.
    The Journal of thoracic and cardiovascular surgery, 2013, Volume: 145, Issue:4

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Thiophenes; Ticlopidine

2013
Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors.
    International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1

    Topics: Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Oligopeptides; Peptide Fragments; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticlopidine

2013
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:12

    Topics: Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Morpholines; Platelet Aggregation; Rivaroxaban; Stents; Swine; Swine, Miniature; Thiophenes; Thrombosis; Ticlopidine

2012
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
    Journal of the American College of Cardiology, 2012, Nov-13, Volume: 60, Issue:20

    Topics: Adolescent; Adult; Aged; Blood Platelets; Body Weight; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticlopidine; Young Adult

2012
Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
    International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome

2013
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
    BMJ case reports, 2012, Oct-26, Volume: 2012

    Topics: Blood Platelets; Clopidogrel; Embolization, Therapeutic; Female; Hemorrhage; Humans; Intracranial Aneurysm; Intracranial Thrombosis; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine; Treatment Outcome

2012
Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition.
    JAMA, 2012, Nov-07, Volume: 308, Issue:17

    Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2012
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Health Care Costs; Hemorrhage; Humans; Insurance, Health, Reimbursement; Kaplan-Meier Estimate; Markov Chains; Medicare; Models, Economic; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States

2013
Trilogy: in search of the lost ring.
    International journal of cardiology, 2013, Aug-20, Volume: 167, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2013
Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs.
    Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:2

    Topics: Animals; Clopidogrel; Dogs; Female; Male; Phenylacetates; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine

2013
Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.
    Platelets, 2013, Volume: 24, Issue:7

    Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2013
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
    Journal of neurointerventional surgery, 2013, Sep-01, Volume: 5, Issue:5

    Topics: Carotid Artery, Internal, Dissection; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2013
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    The American journal of cardiology, 2013, Mar-15, Volume: 111, Issue:6

    Topics: Acute Coronary Syndrome; Aspirin; Chi-Square Distribution; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Statistics, Nonparametric; Thiophenes; Ticlopidine; Treatment Outcome

2013
A pilot study of prasugrel followed by post-procedural maintenance with clopidogrel in patients receiving percutaneous coronary intervention.
    Journal of interventional cardiology, 2013, Volume: 26, Issue:1

    Topics: Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Pilot Projects; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Retrospective Studies; Thiophenes; Ticlopidine

2013
Prasugrel versus clopidogrel for acute coronary syndromes.
    The New England journal of medicine, 2013, 01-10, Volume: 368, Issue:2

    Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine

2013
Prasugrel versus clopidogrel for acute coronary syndromes.
    The New England journal of medicine, 2013, 01-10, Volume: 368, Issue:2

    Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine

2013
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Area Under Curve; Cations; Citrates; Clopidogrel; Coronary Angiography; Female; Hematologic Tests; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Sodium Citrate; Thiophenes; Ticlopidine; Treatment Outcome

2013
High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2013
Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
    Cardiovascular therapeutics, 2013, Volume: 31, Issue:5

    Topics: Aged; Blood Platelets; Cell Communication; Clopidogrel; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2013
Promise and peril of clinical decision support: translating medical evidence to the individual patient.
    Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1

    Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2013
Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:3

    Topics: Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Registries; Thiophenes; Ticlopidine; Treatment Outcome

2013
Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
    Journal of medical economics, 2013, Volume: 16, Issue:4

    Topics: Acute Coronary Syndrome; Age Factors; Clopidogrel; Comorbidity; Cost-Benefit Analysis; Europe; Humans; Markov Chains; Models, Economic; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Turkey

2013
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    The American journal of cardiology, 2013, Apr-01, Volume: 111, Issue:7

    Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Polymerase Chain Reaction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome

2013
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel.
    Cardiology, 2013, Volume: 124, Issue:2

    Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic Neoplasms; Coronary Stenosis; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Drug Therapy, Combination; Drug-Eluting Stents; Fatal Outcome; Female; Humans; Lung Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Time Factors

2013
Letter by Alexopoulos et al regarding article, "pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE Trial".
    Circulation. Cardiovascular interventions, 2013, Volume: 6, Issue:1

    Topics: Aryl Hydrocarbon Hydroxylases; Blood Platelets; Coronary Artery Disease; Drug Substitution; Female; Humans; Male; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2013
Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Substitution; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2013
Switching from prasugrel to clopidogrel: navigating in unknown waters.
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2

    Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2013
Prasugrel use in a patient allergic to clopidogrel: effect of a drug shortage on selection of dual antiplatelet therapy.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Mar-15, Volume: 70, Issue:6

    Topics: Aged; Clopidogrel; Drug Hypersensitivity; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2013
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
    Journal of the American College of Cardiology, 2013, May-21, Volume: 61, Issue:20

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K

2013
Tailoring antiplatelet therapy--insanity or good sense?
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:5

    Topics: Asian People; Clopidogrel; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2013
Thiolactone sulfoxides as new reactive metabolites acting as bis-electrophiles: implication in clopidogrel and prasugrel bioactivation.
    Chemical research in toxicology, 2013, May-20, Volume: 26, Issue:5

    Topics: Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Lactones; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Piperazines; Prasugrel Hydrochloride; Prodrugs; Sulfoxides; Thiophenes; Ticlopidine

2013
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
    Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:4

    Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2013
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
    MMW Fortschritte der Medizin, 2013, Feb-21, Volume: 155, Issue:3

    Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
    Cardiology, 2013, Volume: 124, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
    European journal of clinical investigation, 2013, Volume: 43, Issue:7

    Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Female; Humans; Integrin beta3; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombin; Ticlopidine

2013
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:1

    Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2013
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    The American journal of cardiology, 2013, Aug-01, Volume: 112, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Markov Chains; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine

2013
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
    MMW Fortschritte der Medizin, 2013, Apr-18, Volume: 155, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Industry; Drugs, Generic; Forecasting; Germany; Humans; National Health Programs; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR.
    The American journal of emergency medicine, 2013, Volume: 31, Issue:7

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Emergency Service, Hospital; Female; Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome

2013
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; United States

2013
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; United States

2013
The impact of the environment on diseases and drugs.
    Journal of the American College of Cardiology, 2013, Aug-06, Volume: 62, Issue:6

    Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine

2013
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
    The American journal of emergency medicine, 2013, Volume: 31, Issue:8

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine

2013
Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel.
    The American journal of emergency medicine, 2013, Volume: 31, Issue:8

    Topics: Acute Coronary Syndrome; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine

2013
Upstream antiactivation antiplatelet therapy: first, do no harm. Then consider doing some good.
    The American journal of emergency medicine, 2013, Volume: 31, Issue:9

    Topics: Emergency Service, Hospital; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine

2013
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
    Cardiology, 2013, Volume: 126, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2013
Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Animals; Arthritis, Experimental; Clopidogrel; Cytokines; Female; Granuloma; Inflammation; Joints; Liver; Peptidoglycan; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Rats; Rats, Inbred Lew; Thiophenes; Ticlopidine

2013
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study.
    International journal of cardiology, 2013, Oct-12, Volume: 168, Issue:5

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome

2013
Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel.
    Medical decision making : an international journal of the Society for Medical Decision Making, 2013, Volume: 33, Issue:7

    Topics: Clopidogrel; Drug Monitoring; Humans; Insurance Claim Review; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine

2013
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cell Adhesion Molecules; Cell Separation; Clopidogrel; Enzyme-Linked Immunosorbent Assay; Feasibility Studies; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Ticlopidine

2013
A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching.
    Journal of interventional cardiology, 2013, Volume: 26, Issue:5

    Topics: Angioplasty; Antithrombins; Clopidogrel; Cohort Studies; Drug Combinations; Female; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Piperazines; Postoperative Complications; Prasugrel Hydrochloride; Recombinant Proteins; Retrospective Studies; Thiophenes; Thrombosis; Ticlopidine

2013
TRILOGY ACS: prasugrel of benefit only after angiography?
    Lancet (London, England), 2013, Aug-17, Volume: 382, Issue:9892

    Topics: Angina, Unstable; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2013
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Hemorrhage; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2013
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8

    Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2013
Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
    The American journal of cardiology, 2013, Nov-15, Volume: 112, Issue:10

    Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine; Treatment Outcome

2013
Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel.
    Pharmaceutical research, 2014, Volume: 31, Issue:1

    Topics: Acetates; Animals; Clopidogrel; Esterases; Humans; Hydrolysis; Intestinal Mucosa; Microsomes; Phenylacetates; Prodrugs; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine

2014
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin

2014
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
    The American journal of cardiology, 2013, Dec-15, Volume: 112, Issue:12

    Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Sirolimus; Thiophenes; Ticlopidine; Treatment Outcome

2013
[What kind of antiplatelet treatment in acute coronary syndrome?--Intensive antiplatelet treatment only for patients with invasive strategy].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:45

    Topics: Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine

2013
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:2

    Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Design; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
    The American journal of cardiology, 2014, Jan-01, Volume: 113, Issue:1

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Obesity; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thiophenes; Ticlopidine; United States

2014
Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Circulation. Cardiovascular quality and outcomes, 2013, Volume: 6, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genetic Testing; Genotype; Health Personnel; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Sequence Deletion; Thiophenes; Ticlopidine

2013
Drug interactions with good old clopidogrel: case closed.
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:12

    Topics: Acute Coronary Syndrome; Calcium Channel Blockers; Clopidogrel; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticlopidine

2013
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
    Thrombosis and haemostasis, 2014, Mar-03, Volume: 111, Issue:3

    Topics: Adenosine; Adenosine Diphosphate; Alprostadil; Biomarkers, Pharmacological; Blood Platelets; Bucladesine; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Cyclic AMP; Humans; Iloprost; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Thrombophilia; Ticlopidine

2014
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
    American heart journal, 2014, Volume: 167, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel.
    Cardiovascular therapeutics, 2014, Volume: 32, Issue:1

    Topics: Adult; Aged; Clopidogrel; Electrocardiography; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Thiophenes; Ticlopidine

2014
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.
    Journal of cardiovascular translational research, 2014, Volume: 7, Issue:1

    Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prothrombin; Receptor, PAR-1; Thiophenes; Thrombin; Ticlopidine

2014
P2Y12-based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine

2014
Reply: P2Y12-Based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine

2014
Smoking status and the effects of antiplatelet drugs.
    BMJ (Clinical research ed.), 2013, Oct-01, Volume: 347

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Journal of the American College of Cardiology, 2014, Mar-25, Volume: 63, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2014
Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.
    Drug safety, 2014, Volume: 37, Issue:3

    Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest.
    Resuscitation, 2014, Volume: 85, Issue:5

    Topics: Adenosine; Clopidogrel; Female; Flow Cytometry; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
    The American journal of emergency medicine, 2014, Volume: 32, Issue:5

    Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resistance; Electrocardiography; Heparin; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine

2014
DTB Select: 3 | March 2014.
    Drug and therapeutics bulletin, 2014, Volume: 52, Issue:3

    Topics: Alzheimer Disease; Antibodies, Monoclonal, Murine-Derived; Automobile Driving; Child; Chronic Pain; Clopidogrel; Hepatitis B; Histamine H2 Antagonists; Humans; Hypertension; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proton Pump Inhibitors; Respiratory Tract Infections; Rituximab; Thiophenes; Ticlopidine

2014
Safer heart-attack prevention for seniors with revised drug regimen. Half the normal dose of prasugrel, a lifesaving medication, is just as effective as the larger dose, and reduces risk of serious side effects.
    DukeMedicine healthnews, 2013, Volume: 19, Issue:11

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine

2013
Transient receptor potential ankyrin 1 (TRPA1) channel activation by the thienopyridine-type drugs ticlopidine, clopidogrel, and prasugrel.
    Cell calcium, 2014, Volume: 55, Issue:4

    Topics: Calcium; Calcium Channels; Cell Line; Clopidogrel; Enterochromaffin-like Cells; Gene Expression Regulation; HEK293 Cells; Humans; Mutation; Nerve Tissue Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Serotonin; Thiophenes; Ticlopidine; Time-Lapse Imaging; Transient Receptor Potential Channels; TRPA1 Cation Channel

2014
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Female; Germany; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2014
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Annals of internal medicine, 2014, Feb-18, Volume: 160, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2014
Controversies in acute cardiovascular care.
    European heart journal, 2014, Volume: 35, Issue:9

    Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2014
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.
    Journal of the American Heart Association, 2014, Apr-14, Volume: 3, Issue:2

    Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug Utilization Review; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United States

2014
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.
    European heart journal, 2014, Jun-14, Volume: 35, Issue:23

    Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine

2014
Triple antithrombotic therapy: risky but sometimes necessary.
    Revista espanola de cardiologia (English ed.), 2014, Volume: 67, Issue:3

    Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K

2014
Is it appropriate to compare the results from two clinical trials with one drug in common?
    Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine

2013
Evaluation of comparative treatment effects using indirect comparisons.
    Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2013
Evaluation of comparative treatment effects using indirect comparisons. Response.
    Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine

2013
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics".
    Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Japan; Marketing; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2014
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients.
    Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Economic Competition; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.
    Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Drug Utilization; Evidence-Based Medicine; Humans; International Cooperation; Marketing; Patient Satisfaction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2014
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
    International journal of cardiology, 2014, Jul-01, Volume: 174, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Prasugrel increases the need for platelet transfusions and surgical reexploration rates compared with clopidogrel in coronary artery bypass surgery.
    The Thoracic and cardiovascular surgeon, 2015, Volume: 63, Issue:1

    Topics: Anticoagulants; Clopidogrel; Coronary Artery Bypass; Forecasting; Humans; Logistic Models; Piperazines; Platelet Transfusion; Postoperative Hemorrhage; Prasugrel Hydrochloride; Preoperative Period; Purinergic P2Y Receptor Antagonists; Reoperation; Thiophenes; Ticlopidine

2015
Improving outcomes with bivalirudin in primary percutaneous coronary intervention.
    European heart journal, 2014, Sep-07, Volume: 35, Issue:34

    Topics: Anticoagulants; Clopidogrel; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticlopidine

2014
Concerning antiplatelet therapy.
    The American journal of cardiology, 2014, Jun-15, Volume: 113, Issue:12

    Topics: Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
Concerning antiplatelet therapy. Reply.
    The American journal of cardiology, 2014, Jun-15, Volume: 113, Issue:12

    Topics: Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
Impact of the adjusted dosing regimen of prasugrel for Japanese patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:7

    Topics: Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
Resolution of clopidogrel-associated polyarthritis after conversion to prasugrel.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Jul-01, Volume: 71, Issue:13

    Topics: Aged; Arthritis; Clopidogrel; Humans; Male; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
Uncovering the shroud on antiplatelet therapy for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:6

    Topics: Clopidogrel; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine

2014
The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients.
    Journal of the American College of Cardiology, 2014, Jul-22, Volume: 64, Issue:3

    Topics: Acute Coronary Syndrome; Cause of Death; Female; Humans; Male; Piperazines; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine

2014
Reply: The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients.
    Journal of the American College of Cardiology, 2014, Jul-22, Volume: 64, Issue:3

    Topics: Acute Coronary Syndrome; Cause of Death; Female; Humans; Male; Piperazines; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine

2014
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
    Current medical research and opinion, 2014, Volume: 30, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States

2014
In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry.
    Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:4

    Topics: Acute Disease; Age Factors; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Postoperative Complications; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Registries; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States

2014
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
    Science translational medicine, 2014, Aug-06, Volume: 6, Issue:248

    Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemorrhage; Humans; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency

2014
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:6

    Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recurrence; Registries; Risk Factors; Shock, Cardiogenic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2014
PRASFIT-ACS: important evidence against a "one-guideline-fits-all-races" approach to antiplatelet therapy.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:10

    Topics: Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
PRASFIT-ACS: important evidence against a "one-guideline-fits-all-races" approach to antiplatelet therapy.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:10

    Topics: Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2014
Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.
    Journal of clinical pharmacy and therapeutics, 2014, Volume: 39, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Bayes Theorem; Clopidogrel; Cohort Studies; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2014
Preoperative prasugrel discontinuation management in coronary artery surgery.
    The Thoracic and cardiovascular surgeon, 2015, Volume: 63, Issue:1

    Topics: Coronary Artery Bypass; Humans; Piperazines; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Reoperation; Thiophenes; Ticlopidine

2015
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    BMJ open, 2014, Oct-31, Volume: 4, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine

2014
Dual antiplatelet therapy after drug-eluting stents--how long to treat?
    The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23

    Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine

2014
Antiplatelet therapy: risks and benefits of extended DAPT after stenting.
    Nature reviews. Cardiology, 2015, Volume: 12, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis; Ticlopidine

2015
Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting.
    Hospital practice (1995), 2014, Volume: 42, Issue:4

    Topics: Aged; Clopidogrel; Electronic Health Records; Female; Hospitalization; Hospitals, Urban; Humans; Logistic Models; Male; Medical Audit; Middle Aged; Piperazines; Platelet Aggregation; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2014
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
    BMC cardiovascular disorders, 2014, Dec-16, Volume: 14

    Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine

2014
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI.
    Global heart, 2014, Volume: 9, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Societies, Medical; Thiophenes; Ticagrelor; Ticlopidine; World Health Organization

2014
Reply by the authors of the original article.
    The Thoracic and cardiovascular surgeon, 2015, Volume: 63, Issue:1

    Topics: Coronary Artery Bypass; Humans; Piperazines; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Reoperation; Thiophenes; Ticlopidine

2015
Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding.
    Evidence-based medicine, 2015, Volume: 20, Issue:3

    Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine

2015
Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury.
    The Kaohsiung journal of medical sciences, 2015, Volume: 31, Issue:3

    Topics: Animals; Anticoagulants; Aryldialkylphosphatase; Aspirin; Cardiotonic Agents; Clopidogrel; Dipeptidases; Drug Evaluation, Preclinical; Enoxaparin; Femoral Artery; Heparin, Low-Molecular-Weight; Hindlimb; Kidney; Male; Malondialdehyde; Morpholines; Myocardium; Nitric Oxide; Oxidative Stress; Rats, Sprague-Dawley; Reperfusion Injury; Rivaroxaban; Thiophenes; Ticlopidine

2015
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
    The American journal of cardiology, 2015, May-01, Volume: 115, Issue:9

    Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine

2015
Balancing the risks and benefits of dual platelet inhibition.
    The New England journal of medicine, 2015, May-07, Volume: 372, Issue:19

    Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2015
ACP journal club. Dual antiplatelets for 30 mo after drug-eluting stents reduced stent thrombosis and CV and cerebrovascular events.
    Annals of internal medicine, 2015, Mar-17, Volume: 162, Issue:6

    Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine

2015
Synthesis of the alkylated active metabolite of tipidogrel.
    Bioorganic & medicinal chemistry letters, 2015, Apr-15, Volume: 25, Issue:8

    Topics: Alkylation; Animals; Chromatography, High Pressure Liquid; Clopidogrel; Half-Life; Piperidines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Tandem Mass Spectrometry; Thiophenes; Ticlopidine

2015
Duration of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14

    Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine

2015
Duration of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14

    Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine

2015
Duration of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14

    Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine

2015
Duration of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14

    Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine

2015
Duration of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14

    Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine

2015
Duration of dual antiplatelet therapy after drug-eluting stents.
    The New England journal of medicine, 2015, 04-02, Volume: 372, Issue:14

    Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine

2015
Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decision.
    Heart (British Cardiac Society), 2015, Volume: 101, Issue:11

    Topics: Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine

2015
Lights and Shadows of Antiplatelet Therapy in Primary Percutaneous Coronary Intervention.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:7

    Topics: Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine

2015
Reply: Lights and Shadows of Antiplatelet Therapy in Primary Percutaneous Coronary Intervention.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:7

    Topics: Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine

2015
An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes.
    Thrombosis research, 2015, Volume: 136, Issue:6

    Topics: Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine

2015
Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.
    JACC. Cardiovascular interventions, 2016, Feb-08, Volume: 9, Issue:3

    Topics: Acute Coronary Syndrome; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome

2016
Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration.
    Molecules (Basel, Switzerland), 2016, May-30, Volume: 21, Issue:6

    Topics: Adenosine Diphosphate; Animals; Clopidogrel; Hydrolysis; Male; Metabolic Networks and Pathways; Models, Molecular; Molecular Conformation; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Thiophenes; Ticlopidine

2016
Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus.
    Circulation, 2016, Sep-13, Volume: 134, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome

2016
The FDA-approved drugs ticlopidine, sertaconazole, and dexlansoprazole can cause morphological changes in C. elegans.
    Chemosphere, 2020, Volume: 261

    Topics: Animals; Bioaccumulation; Caenorhabditis elegans; Dexlansoprazole; Drug Approval; Epigenesis, Genetic; Humans; Imidazoles; Larva; Molting; Mutation; Thiophenes; Ticlopidine; United States; United States Food and Drug Administration

2020
Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2022, Oct-01, Volume: 177

    Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Galanin; Humans; Phenylacetates; Platelet Aggregation Inhibitors; Substance P; Thiophenes; Ticlopidine

2022